0001792044-22-000017 | 10-Q | XBRL Viewer

Print Document View Excel Document

Pension and Other Postretirement Benefit (Narrative) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plans, estimated benefit payments, in current fiscal year	$ 118.0
Estimated employer contributions in current year	$ 52.0

Segment Information (Policies)	3 Months Ended
Segment Information (Policies)	Mar. 31, 2022
Segment Reporting [Abstract]
Segment Reporting Policy	Viatris has four reportable segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Company reports segment information on the basis of markets and geography, which reflects its focus on bringing its broad and diversified portfolio of branded, complex generics and biosimilars, and generic products to people in markets everywhere. Our Developed Markets segment comprises our operations primarily in North America and Europe. Our Greater China segment includes our operations in China, Taiwan and Hong Kong. Our JANZ segment reflects our operations in Japan, Australia and New Zealand. Our Emerging Markets segment encompasses our presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company’s ARV franchise. The Company’s chief operating decision maker is the Chief Executive Officer, who evaluates the performance of its segments based on total revenues and segment profitability. Certain costs are not included in the measurement of segment profitability, such as costs, if any, associated with the following: ◦Intangible asset amortization expense and impairments of intangible assets; ◦R&D expense; ◦Net charges or net gains for litigation settlements and other contingencies; ◦Certain costs related to transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory and property, plant and equipment; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) other significant items, which are substantive and/or unusual, and in some cases recurring, items (such as restructuring) that are evaluated on an individual basis by management and that either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such special items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities. ◦Corporate and other unallocated costs associated with platform functions (such as digital, facilities, legal, finance, human resources, insurance, public affairs and procurement), patient advocacy activities and certain compensation and other corporate costs (such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing, which include manufacturing variances associated with production) and operations that are not directly assessed to an operating segment as business unit (segment) management does not manage these costs. The Company does not report depreciation expense, total assets and capital expenditures by segment, as such information is not used by the chief operating decision maker. The accounting policies of the segments are the same as those described in Note 2 Summary of Significant Accounting Policies included in the 2021 Form 10-K, and Note 3 Recent Accounting Pronouncements included in this Form 10-Q.

Revenue Recognition and Accounts Receivable (Accounts Receivable, Net) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Revenue Recognition And Accounts Receivable [Line Items]
Trade receivables, net	$ 3,556.9	$ 3,774.4
Other receivables	537.0	492.0
Accounts receivable, net	4,093.9	4,266.4
Variable Consideration
Revenue Recognition And Accounts Receivable [Line Items]
Trade receivables, net	1,707.1	1,688.6
Other receivables	1,095.8	1,362.1
Accounts receivable, net	$ 2,802.9	$ 3,050.7

Equity Method Investments (Narrative) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)
Schedule of Equity Method Investments [Line Items]
Equity method investments summarized financial data basis	100.00%
Loss from equity method investments	$ (0.1)	$ 17.9
Clean energy investments
Schedule of Equity Method Investments [Line Items]
Number of equity method investments	3

General (Details) - TURKEY - Unusual or Infrequent Item, or Both	3 Months Ended
	Mar. 31, 2022
Unusual Risk or Uncertainty [Line Items]
Percent Of Net Sales Impacted, High Inflationary Economy	1.00%
Percent Of Total Assets Impacted, High Inflationary Economy	1.00%

Share-Based Incentive Plan (Narrative) (Details) - USD ($) $ in Millions		3 Months Ended
	Nov. 16, 2020	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award expiration period, in years		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		5,126,329		5,576,490
Long-Term Incentive Plan 2003
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	6,757,640
Total unrecognized compensation expense, net of estimated forfeitures		$ 272.7
Weighted-average period over which total unrecognized compensation expense expected to be recognized, in years		2 years
Intrinsic value of stock-based awards exercised and restricted stock units converted		$ 63.1	$ 30.8
Common Stock, Capital Shares Reserved for Future Issuance	13,535,627
Long-Term Incentive Plan 2003 \| Stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average remaining contractual term for stock awards outstanding, in years		4 years 8 months 12 days
Average remaining contractual term for stock awards vested and expected to vest, in years		4 years 7 months 6 days
Average remaining contractual term for stock awards exercisable, in years		4 years 6 months
Long-Term Incentive Plan 2003 \| Stock awards \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years		3 years
Long-Term Incentive Plan 2003 \| Stock awards \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years		4 years
2020 Stock Incentive Plan and 2003 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary shares reserved for issuance	72,500,000

Equity Method Investments

3 Months Ended

Mar. 31, 2022

Equity Method Investments and Joint Ventures [Abstract]

Equity Method Investments

The law that provides for IRC Section 45 tax credits expired during the year ended December 31, 2021 for all three clean energy investments and all of the clean energy investments have wound down operations. Summarized financial information, in the aggregate, for the Company’s three equity method, clean energy investments on a 100% basis for the three months ended March 31, 2021 are as follows:


	Three Months Ended

(In millions)		March 31, 2021
Total revenues		$	109.5
Gross loss		(1.4)
Operating and non-operating expense		4.9
Net loss		$	(6.3)

The Company’s net losses from its equity method investments included amortization expense related to the excess of the cost basis of the Company’s investment over the underlying assets of each individual investee. For the three months ended March 31, 2021, the Company recognized net losses from equity method investments of $17.9 million, which were recognized as a component of other expense, net in the condensed consolidated statements of operations. The Company recognized the income tax credits and benefits from the clean energy investments as part of its provision for income taxes.

Segment Information

3 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Segment Information

Viatris has four reportable segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Company reports segment information on the basis of markets and geography, which reflects its focus on bringing its broad and diversified portfolio of branded, complex generics and biosimilars, and generic products to people in markets everywhere. Our Developed Markets segment comprises our operations primarily in North America and Europe. Our Greater China segment includes our operations in China, Taiwan and Hong Kong. Our JANZ segment reflects our operations in Japan, Australia and New Zealand. Our Emerging Markets segment encompasses our presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company’s ARV franchise.

The Company’s chief operating decision maker is the Chief Executive Officer, who evaluates the performance of its segments based on total revenues and segment profitability.

Certain costs are not included in the measurement of segment profitability, such as costs, if any, associated with the following:

◦Intangible asset amortization expense and impairments of intangible assets;

◦R&D expense;

◦Net charges or net gains for litigation settlements and other contingencies;

◦Certain costs related to transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory and property, plant and equipment; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) other significant items, which are substantive and/or unusual, and in some cases recurring, items (such as restructuring) that are evaluated on an individual basis by management and that either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such special items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.

◦Corporate and other unallocated costs associated with platform functions (such as digital, facilities, legal, finance, human resources, insurance, public affairs and procurement), patient advocacy activities and certain compensation and other corporate costs (such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing, which include manufacturing variances associated with production) and operations that are not directly assessed to an operating segment as business unit (segment) management does not manage these costs.

The Company does not report depreciation expense, total assets and capital expenditures by segment, as such information is not used by the chief operating decision maker.

The accounting policies of the segments are the same as those described in Note 2 Summary of Significant Accounting Policies included in the 2021 Form 10-K, and Note 3 Recent Accounting Pronouncements included in this Form 10-Q.

Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information.


	Net Sales				Segment Profitability
	Three Months Ended March 31,				Three Months Ended March 31,

(In millions)	2022		2021		2022		2021
Reportable Segments:
Developed Markets	$	2,476.1	$	2,571.6	$	1,211.5	$	1,285.4
Greater China	573.1		591.9		417.7		404.9
JANZ	423.8		481.9		174.3		184.2
Emerging Markets	705.2		754.7		345.3		337.3
Total reportable segments	$	4,178.2	$	4,400.1	$	2,148.8	$	2,211.8

Reconciling items:
Intangible asset amortization expense					(648.1)		(684.4)
Intangible asset impairment charges					—		(83.4)
Globally managed research and development costs					(142.3)		(184.1)
Litigation settlements & other contingencies					(6.2)		(22.9)
Transaction related and other special items					(185.6)		(993.4)
Corporate and other unallocated					(459.2)		(509.8)
Earnings (loss) from operations					$	707.4	$	(266.2)

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Collaboration and Licensing Agreements (Details) - Maximum $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments	$ 338.0
Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments	$ 10.0

Restructuring (Restructuring Charges) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2022
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 296.7
Charges	16.8
Cash payment	(83.8)
Utilization	(4.2)
Foreign currency translation	(2.2)
Ending Balance	223.3	$ 296.7
Maximum \| 2020 Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Settled without Cash	450.0
Restructuring Reserve [Roll Forward]
Charges		1,400.0
Maximum \| 2020 Restructuring Plan \| Scenario, Forecast
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost Remaining			$ 950.0
Developed Markets
Restructuring Reserve [Roll Forward]
Charges	12.7
Greater China
Restructuring Reserve [Roll Forward]
Charges	1.3
JANZ
Restructuring Reserve [Roll Forward]
Charges	0.1
Emerging Markets
Restructuring Reserve [Roll Forward]
Charges	2.6
Corporate and Other
Restructuring Reserve [Roll Forward]
Charges	0.1
Employee Related Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	292.6
Charges	7.3
Cash payment	(77.6)
Utilization	0.0
Foreign currency translation	(2.1)
Ending Balance	220.2	292.6
Other Exit Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	4.1
Charges	9.5
Cash payment	(6.2)
Utilization	(4.2)
Foreign currency translation	(0.1)
Ending Balance	$ 3.1	$ 4.1

Comprehensive Earnings

3 Months Ended

Mar. 31, 2022

Equity [Abstract]

Comprehensive Earnings

Comprehensive Loss

Accumulated other comprehensive loss, as reflected on the condensed consolidated balance sheets, is comprised of the following:


(In millions)	March 31, 2022		December 31, 2021
Accumulated other comprehensive loss:
Net unrealized gain on marketable securities, net of tax	$	(1.3)	$	—
Net unrecognized loss and prior service cost related to defined benefit plans, net of tax	29.4		32.2
Net unrecognized loss on derivatives in cash flow hedging relationships, net of tax	9.4		9.2
Net unrecognized loss on derivatives in net investment hedging relationships, net of tax	173.1		16.7
Foreign currency translation adjustment	(2,271.6)		(1,802.4)
	$	(2,061.0)	$	(1,744.3)

Components of accumulated other comprehensive loss, before tax, consist of the following, for the three months ended March 31, 2022 and 2021:


	Three Months Ended March 31, 2022
	Gains and Losses on Derivatives in Cash Flow Hedging Relationships				Gains and Losses on Net Investment Hedges		Gains and Losses on Marketable Securities		Defined Pension Plan Items		Foreign Currency Translation Adjustment		Totals
(In millions)	Foreign Currency Forward Contracts	Interest Rate Swaps	Total
Balance at December 31, 2021, net of tax			$	9.2	$	16.7	$	—	$	32.2	$	(1,802.4)	$	(1,744.3)
Other comprehensive earnings (loss) before reclassifications, before tax			13.3		201.3		(1.7)		(2.7)		(469.2)		(259.0)
Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales	(14.2)		(14.2)										(14.2)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense		1.1	1.1										1.1
Amortization of prior service costs included in SG&A									0.1				0.1

Net other comprehensive earnings (loss), before tax			0.2		201.3		(1.7)		(2.6)		(469.2)		(272.0)
Income tax provision (benefit)			—		44.9		(0.4)		0.2		—		44.7

Balance at March 31, 2022, net of tax			$	9.4	$	173.1	$	(1.3)	$	29.4	$	(2,271.6)	$	(2,061.0)


	Three Months Ended March 31, 2021
	Gains and Losses on Derivatives in Cash Flow Hedging Relationships				Gains and Losses on Net Investment Hedges		Gains and Losses on Marketable Securities		Defined Pension Plan Items		Foreign Currency Translation Adjustment		Totals
(In millions)	Foreign Currency Forward Contracts	Interest Rate Swaps	Total
Balance at December 31, 2020, net of tax			$	(18.0)	$	(353.6)	$	1.2	$	(26.1)	$	(461.5)	$	(858.0)
Other comprehensive earnings (loss) before reclassifications, before tax			8.3		227.4		(0.9)		0.6		(721.2)		(485.8)
Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales	(6.1)		(6.1)										(6.1)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense		1.1	1.1										1.1
Amortization of prior service costs included in SG&A									(0.1)				(0.1)
Amortization of actuarial gain included in SG&A									0.3				0.3
Net other comprehensive earnings (loss), before tax			3.3		227.4		(0.9)		0.8		(721.2)		(490.6)
Income tax provision			0.8		35.1		0.1		1.0		—		37.0

Balance at March 31, 2021, net of tax			$	(15.5)	$	(161.3)	$	0.2	$	(26.3)	$	(1,182.7)	$	(1,385.6)

Financial Instruments and Risk Management (Effect Of Derivative Instruments on the Condensed Consolidated Statements of Operations Derivatives in Cash Flow Hedging Relationships) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	$ 13.1	$ 5.0
Gain (Loss) on Fair Value Hedges Recognized in Earnings	21.7	35.6
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	165.1	263.4
Foreign currency forward contracts \| Other expense
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net	21.7	35.6
Cash Flow Hedging \| Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	9.7	5.6
Cash Flow Hedging \| Foreign currency forward contracts \| Sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	14.2	6.1
Cash Flow Hedging \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	(0.9)	(0.8)
Cash Flow Hedging \| Interest rate swaps \| Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	(1.1)	(1.1)
Net Investment Hedging \| Foreign currency forward contracts \| Gains and Losses on Derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	$ 156.3	$ 258.6

Debt (2016 and 2018 Revolving Facility and 2016 Term Facility) (Narrative) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Current portion of long-term debt	$ 2,595.4	$ 1,860.3

Restructuring (Tables)

3 Months Ended

Mar. 31, 2022

Restructuring and Related Activities [Abstract]

Restructuring - employee related

The following table summarizes the restructuring charges and the reserve activity for the 2020 restructuring program from December 31, 2021 to March 31, 2022:


(In millions)	Employee Related Costs		Other Exit Costs		Total
Balance at December 31, 2021:	$	292.6	$	4.1	$	296.7
Charges (1)	7.3		9.5		16.8

Cash payment	(77.6)		(6.2)		(83.8)
Utilization	—		(4.2)		(4.2)
Foreign currency translation	(2.1)		(0.1)		(2.2)
Balance at March 31, 2022:	$	220.2	$	3.1	$	223.3

____________

(1) For the three months ended March 31, 2022, total restructuring charges in Developed Markets, Emerging Markets, Greater China, JANZ, Emerging Markets and Corporate/Other were approximately $12.7 million, $2.6 million, $1.3 million, $0.1 million, and $0.1 million, respectively.

Balance Sheet Components (Tables)

3 Months Ended

Mar. 31, 2022

Balance Sheet Components [Abstract]

Schedule of Cash, cash equivalents, and restricted cash

Cash and restricted cash


(In millions)	March 31, 2022		December 31, 2021		March 31, 2021
Cash and cash equivalents	$	752.4	$	701.2	$	806.9
Restricted cash, included in prepaid expenses and other current assets	5.0		5.0		6.2
Cash, cash equivalents and restricted cash	$	757.4	$	706.2	$	813.1

Inventories


(In millions)	March 31, 2022		December 31, 2021
Raw materials	$	868.1	$	922.4
Work in process	767.5		993.3
Finished goods	2,161.7		2,062.0
Inventories	$	3,797.3	$	3,977.7

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets


(In millions)	March 31, 2022		December 31, 2021
Prepaid expenses	$	268.1	$	256.7

Available-for-sale fixed income securities	36.6		38.2
Fair value of financial instruments	202.8		144.6
Equity securities	48.0		51.0
Other current assets	1,208.1		1,467.1
Prepaid expenses and other current assets	$	1,763.6	$	1,957.6

Property, Plant and Equipment

Property, plant and equipment, net


(In millions)	March 31, 2022		December 31, 2021
Machinery and equipment	$	2,845.8	$	3,054.0
Buildings and improvements	1,578.4		1,808.5
Construction in progress	541.8		588.7
Land and improvements	126.5		137.9
Gross property, plant and equipment	5,092.5		5,589.1
Accumulated depreciation	1,942.3		2,400.5
Property, plant and equipment, net	$	3,150.2	$	3,188.6

Other Assets

Other assets


(In millions)	March 31, 2022		December 31, 2021

Operating lease right-of-use assets	$	281.7	$	290.8
Other long-term assets	774.3		879.9
Other assets	$	1,056.0	$	1,170.7

Accounts payable


(In millions)	March 31, 2022		December 31, 2021
Trade accounts payable	$	928.4	$	1,056.1
Other payables	571.2		601.3
Accounts payable	$	1,499.6	$	1,657.4

Other Current Liabilities

Other current liabilities


(In millions)	March 31, 2022		December 31, 2021
Accrued sales allowances	$	1,095.8	$	1,362.1
Legal and professional accruals, including litigation accruals	694.9		715.6
Payroll and employee benefit liabilities	567.1		741.9
Contingent consideration	86.2		66.7
Accrued restructuring	171.8		233.5
Accrued interest	228.8		86.6

Equity method investments, clean energy investments	4.3		10.9
Fair value of financial instruments	98.9		61.0
Operating lease liability	89.9		86.7
Other	1,388.6		1,254.6
Other current liabilities	$	4,426.3	$	4,619.6

Other Noncurrent Liabilities

Other long-term obligations


(In millions)	March 31, 2022		December 31, 2021
Employee benefit liabilities	$	861.3	$	876.4
Contingent consideration	112.2		133.0

Tax related items, including contingencies	429.5		426.1
Operating lease liability	191.7		200.9
Accrued restructuring	51.4		64.3
Other	238.2		232.9
Other long-term obligations	$	1,884.3	$	1,933.6

Disposal Groups, Including Discontinued Operations

The amounts associated with the biosimilars portfolio classified as held for sale consisted of the following:


	As of
(In millions)	March 31, 2022
Assets held for sale
Accounts receivable, net	$	136.1
Inventories	122.4
Prepaid expenses and other current assets	12.5
Intangible assets, net	7.5
Goodwill	953.0
Other assets	105.6
Total assets held for sale	$	1,337.1

Liabilities held for sale
Accounts payable	$	95.4
Other current liabilities	182.3
Total liabilities held for sale	$	277.7

Equity Method Investments (Income Statement) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Schedule of Equity Method Investments [Line Items]
Revenues	$ 4,191.7	$ 4,430.3
Gross loss	1,771.2	1,127.3
Operating and non-operating expense	$ 527.5	(441.3)
Consolidated Entity
Schedule of Equity Method Investments [Line Items]
Revenues		109.5
Gross loss		(1.4)
Operating and non-operating expense		4.9
Net loss		$ (6.3)

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

+ Details

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

Financial Instruments and Risk Management (Narrative) (Details) € in Millions, ¥ in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($)	Mar. 31, 2022 EUR (€)	Mar. 31, 2022 JPY (¥)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 JPY (¥)
Derivative [Line Items]
Proceeds from sale of terminated interest rate swaps \| $	$ 45.0
Pre-tax net losses on cash flow hedges to be reclassified from AOCE into earnings in next twelve months \| $	22.0
2020 Euro Senior Notes
Derivative [Line Items]
Long-term debt \| $	328.7			$ 347.6
YEN Term Loan
Derivative [Line Items]
Long-term debt \| $	$ 328.7
Net Investment Hedging
Derivative [Line Items]
Notional amount of derivative		€ 5,850.0	¥ 40,000		€ 5,850.0	¥ 40,000
Long-term debt		5,850.0	40,000
Net Investment Hedging \| 2024 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative		1,000.0			1,000.0
Long-term debt		1,000.0
Net Investment Hedging \| 2028 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative		750.0			750.0
Long-term debt		750.0
Net Investment Hedging \| 2.125% Euro Senior Notes due 2025
Derivative [Line Items]
Notional amount of derivative		500.0			500.0
Long-term debt		500.0
Net Investment Hedging \| 2022 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative		750.0			750.0
Long-term debt		750.0
Net Investment Hedging \| 2024 Euro Senior Notes, 1.023%
Derivative [Line Items]
Notional amount of derivative		750.0			750.0
Long-term debt		750.0
Net Investment Hedging \| 2027 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative		850.0			850.0
Long-term debt		850.0
Net Investment Hedging \| 2032 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative		1,250.0			€ 1,250.0
Long-term debt		€ 1,250.0
Net Investment Hedging \| YEN Term Loan
Derivative [Line Items]
Notional amount of derivative \| ¥			40,000			¥ 40,000
Long-term debt \| ¥			¥ 40,000
Measurement Input, Discount Rate \| Contingent consideration
Derivative [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.080	0.080	0.080

Comprehensive Earnings (Tables)

3 Months Ended

Mar. 31, 2022

Equity [Abstract]

Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss, as reflected on the condensed consolidated balance sheets, is comprised of the following:


(In millions)	March 31, 2022		December 31, 2021
Accumulated other comprehensive loss:
Net unrealized gain on marketable securities, net of tax	$	(1.3)	$	—
Net unrecognized loss and prior service cost related to defined benefit plans, net of tax	29.4		32.2
Net unrecognized loss on derivatives in cash flow hedging relationships, net of tax	9.4		9.2
Net unrecognized loss on derivatives in net investment hedging relationships, net of tax	173.1		16.7
Foreign currency translation adjustment	(2,271.6)		(1,802.4)
	$	(2,061.0)	$	(1,744.3)

Components of Other Comprehensive Loss

Components of accumulated other comprehensive loss, before tax, consist of the following, for the three months ended March 31, 2022 and 2021:


	Three Months Ended March 31, 2022
	Gains and Losses on Derivatives in Cash Flow Hedging Relationships				Gains and Losses on Net Investment Hedges		Gains and Losses on Marketable Securities		Defined Pension Plan Items		Foreign Currency Translation Adjustment		Totals
(In millions)	Foreign Currency Forward Contracts	Interest Rate Swaps	Total
Balance at December 31, 2021, net of tax			$	9.2	$	16.7	$	—	$	32.2	$	(1,802.4)	$	(1,744.3)
Other comprehensive earnings (loss) before reclassifications, before tax			13.3		201.3		(1.7)		(2.7)		(469.2)		(259.0)
Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales	(14.2)		(14.2)										(14.2)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense		1.1	1.1										1.1
Amortization of prior service costs included in SG&A									0.1				0.1

Net other comprehensive earnings (loss), before tax			0.2		201.3		(1.7)		(2.6)		(469.2)		(272.0)
Income tax provision (benefit)			—		44.9		(0.4)		0.2		—		44.7

Balance at March 31, 2022, net of tax			$	9.4	$	173.1	$	(1.3)	$	29.4	$	(2,271.6)	$	(2,061.0)


	Three Months Ended March 31, 2021
	Gains and Losses on Derivatives in Cash Flow Hedging Relationships				Gains and Losses on Net Investment Hedges		Gains and Losses on Marketable Securities		Defined Pension Plan Items		Foreign Currency Translation Adjustment		Totals
(In millions)	Foreign Currency Forward Contracts	Interest Rate Swaps	Total
Balance at December 31, 2020, net of tax			$	(18.0)	$	(353.6)	$	1.2	$	(26.1)	$	(461.5)	$	(858.0)
Other comprehensive earnings (loss) before reclassifications, before tax			8.3		227.4		(0.9)		0.6		(721.2)		(485.8)
Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales	(6.1)		(6.1)										(6.1)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense		1.1	1.1										1.1
Amortization of prior service costs included in SG&A									(0.1)				(0.1)
Amortization of actuarial gain included in SG&A									0.3				0.3
Net other comprehensive earnings (loss), before tax			3.3		227.4		(0.9)		0.8		(721.2)		(490.6)
Income tax provision			0.8		35.1		0.1		1.0		—		37.0

Balance at March 31, 2021, net of tax			$	(15.5)	$	(161.3)	$	0.2	$	(26.3)	$	(1,182.7)	$	(1,385.6)

Condensed Consolidated Statements Of Comprehensive Loss - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Net earnings (loss) attributable to Viatris Inc. common shareholders	$ 399.2	$ (1,037.6)
Other comprehensive loss, before tax:
Foreign currency translation adjustment	(469.2)	(721.2)
Change in unrecognized (loss) gain and prior service cost related to defined benefit plans	(2.6)	0.8
Net unrealized loss on marketable securities	(1.7)	(0.9)
Other comprehensive loss, before tax	(272.0)	(490.6)
Income tax provision	44.7	37.0
Other comprehensive loss, net of tax	(316.7)	(527.6)
Comprehensive earnings (loss)	82.5	(1,565.2)
Cash Flow Hedging
Other comprehensive loss, before tax:
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax	0.2	3.3
Net Investment Hedging
Other comprehensive loss, before tax:
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax	$ 201.3	$ 227.4

Goodwill and Intangible Assets (Amortization Expense) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible asset amortization expense	$ 648.1	$ 684.4
Intangible asset impairment charges	0.0	83.4
Total intangible asset amortization expense (including impairment charges)	$ 648.1	$ 767.8

Balance Sheet Components (Cash, cash equivalents, and restricted cash) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 752.4	$ 701.2	$ 806.9
Restricted cash	5.0	5.0	6.2
Cash, cash equivalents and restricted cash	$ 757.4	$ 706.2	$ 813.1	$ 850.0

Litigation (Pricing and Medicaid Litigation) (Narrative) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Loss Contingencies [Line Items]
Other current liabilities	$ 4,426.3	$ 4,619.6

Comprehensive Earnings (Components Of Other Comprehensive Loss) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrealized gain (loss) on marketable securities, net of tax, beginning of period	$ 0.0
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax	(29.4)		$ 32.2
Foreign currency translation adjustment, beginning of period	(1,802.4)
Accumulated other comprehensive loss, net of tax, beginning of period	(1,744.3)
Net sales	4,178.2	$ 4,400.1
Interest expense	146.2	169.0
Net unrealized loss on marketable securities	(1.7)	(0.9)
Change in unrecognized gain and prior service cost related to defined benefit plans	(2.6)	0.8
Other comprehensive loss, before tax	(272.0)	(490.6)
Income Tax Expense (Benefit)	128.3	596.3
Net unrealized gain (loss) on marketable securities, net of tax, end of period	(1.3)
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, end of period	(29.4)
Foreign currency translation adjustment, end of period	(2,271.6)
Accumulated other comprehensive loss, net of tax, end of period	(2,061.0)
Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gains (losses) on derivatives, net of tax, beginning of period		(18.0)
Other comprehensive earnings (loss) before reclassifications, before tax		8.3
Income Tax Expense (Benefit)		0.8
Net unrecognized gains (losses) on derivatives, net of tax, end of period		(15.5)
Gains and Losses on Derivatives \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses on derivatives in net investment hedging relationships, net of tax		3.3
Gains and Losses on Derivatives \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Foreign currency forward contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(14.2)	(6.1)
Gains and Losses on Derivatives \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Interest rate swaps
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.1	1.1
Gains and Losses on Marketable Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrealized gain (loss) on marketable securities, net of tax, beginning of period		1.2
Other comprehensive earnings (loss) before reclassifications, before tax		(0.9)
Income Tax Expense (Benefit)		0.1
Net unrealized gain (loss) on marketable securities, net of tax, end of period		0.2
Gains and Losses on Marketable Securities \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income Tax Expense (Benefit)	(0.4)
Defined Benefit Plan Items
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax		(26.3)		$ (26.1)
Other comprehensive earnings (loss) before reclassifications, before tax	(2.7)	0.6
Income Tax Expense (Benefit)		(1.0)
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, end of period		(26.3)
Defined Benefit Plan Items \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs		0.1
Change in unrecognized gain and prior service cost related to defined benefit plans		0.8
Income Tax Expense (Benefit)	0.2
Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Foreign currency translation adjustment, beginning of period		(461.5)
Other comprehensive earnings (loss) before reclassifications, before tax	(469.2)
Income Tax Expense (Benefit)		0.0
Foreign currency translation adjustment, end of period		(1,182.7)
Foreign Currency Translation Adjustment \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive loss, before tax		(721.2)
Income Tax Expense (Benefit)	0.0
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, net of tax, beginning of period		(858.0)
Other comprehensive earnings (loss) before reclassifications, before tax	(259.0)	(485.8)
Income Tax Expense (Benefit)		37.0
Accumulated other comprehensive loss, net of tax, end of period		(1,385.6)
AOCI Attributable to Parent [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs	0.1	(0.1)
Other comprehensive earnings (loss), reclassification adjustment from AOCE, pension and other postretirement benefit plans, for net gain (loss), before tax		0.3
Income Tax Expense (Benefit)	44.7
AOCI Attributable to Parent [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Foreign currency forward contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(14.2)	(6.1)
AOCI Attributable to Parent [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Interest rate swaps
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.1	1.1
Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses on derivatives in net investment hedging relationships, net of tax	0.2
Cash Flow Hedging \| Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gains (losses) on derivatives, net of tax, beginning of period	9.2
Other comprehensive earnings (loss) before reclassifications, before tax	13.3
Income Tax Expense (Benefit)	0.0
AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax	9.4
Cash Flow Hedging \| Gains and Losses on Derivatives \| Foreign currency forward contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(14.2)
Cash Flow Hedging \| Gains and Losses on Derivatives \| Interest rate swaps
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.1
Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulate Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Net Investment Hedges, Effect Net of Taxx	173.1		$ 16.7
Net Investment Hedging \| Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gains (losses) on derivatives, net of tax, beginning of period		(353.6)
Other comprehensive earnings (loss) before reclassifications, before tax		227.4
Income Tax Expense (Benefit)	44.9	35.1
Net unrecognized gains (losses) on derivatives, net of tax, end of period		(161.3)
Mylan N.V. \| Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses on derivatives in net investment hedging relationships, net of tax	201.3	227.4
Pension and other postretirement benefits
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs	0.1	(0.1)
Recognized net actuarial losses	0.0	$ 0.3
Pension and other postretirement benefits \| Defined Benefit Plan Items \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs	$ 0.1

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Treasury Stock	Accumulated Other Comprehensive Loss
Balance at Dec. 31, 2020	$ 22,954.1	$ 12.1	$ 18,438.8	$ 5,361.2	$ 0.0	$ (858.0)
Balance (in shares) at Dec. 31, 2020		1,206,895,644
Balance (in shares) at Dec. 31, 2020					0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (loss)	(1,037.6)
Other comprehensive loss, net of tax	(527.6)					(527.6)
Issuance of restricted stock, net of shares withheld (in shares)		1,635,326
Issuance of restricted stock, net of shares withheld	0.0		0.0
Taxes related to the net share settlement of equity awards	(6.9)		(6.9)
Stock compensation expense	32.7		32.7
Balance at Mar. 31, 2021	21,414.7	$ 12.1	18,464.6	4,323.6	$ 0.0	(1,385.6)
Balance (in shares) at Mar. 31, 2021		1,208,530,970
Balance (in shares) at Mar. 31, 2021					0
Balance at Dec. 31, 2021	20,492.7	$ 12.1	18,536.1	3,688.8	$ 0.0	(1,744.3)
Balance (in shares) at Dec. 31, 2021		1,209,507,463
Balance (in shares) at Dec. 31, 2021					0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (loss)	399.2
Other comprehensive loss, net of tax	(316.7)					(316.7)
Issuance of restricted stock, net of shares withheld (in shares)		2,816,020
Issuance of restricted stock, net of shares withheld	0.0	$ 0.0	0.0
Taxes related to the net share settlement of equity awards	(9.3)		(9.3)
Stock compensation expense	28.3		28.3
Balance at Mar. 31, 2022	$ 20,447.7	$ 12.1	$ 18,555.1	3,941.5	$ 0.0	$ (2,061.0)
Balance (in shares) at Mar. 31, 2022		1,212,323,483
Balance (in shares) at Mar. 31, 2022					0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Dividends, Common Stock, Cash				$ (146.5)

Pensions and Other Postretirement Benefits (Tables)

3 Months Ended

Mar. 31, 2022

Retirement Benefits [Abstract]

Net Periodic Benefit Cost

Components of net periodic benefit cost for the three months ended March 31, 2022 and 2021 were as follows:


		Pension and Other Postretirement Benefits
	Three Months Ended
	March 31,
(In millions)		2022		2021
Service cost		$	9.5	$	10.8
Interest cost		10.4		8.5
Expected return on plan assets		(16.6)		(16.5)
Amortization of prior service costs		0.1		(0.1)
Recognized net actuarial losses		—		0.3
Net periodic benefit cost		$	3.4	$	3.0

Equity Method Investments (Tables)

3 Months Ended

Mar. 31, 2022

Equity Method Investments and Joint Ventures [Abstract]

Equity Method Investments

Summarized financial information, in the aggregate, for the Company’s three equity method, clean energy investments on a 100% basis for the three months ended March 31, 2021 are as follows:


	Three Months Ended

(In millions)		March 31, 2021
Total revenues		$	109.5
Gross loss		(1.4)
Operating and non-operating expense		4.9
Net loss		$	(6.3)

Pensions and Other Postretirement Benefits

3 Months Ended

Mar. 31, 2022

Retirement Benefits [Abstract]

Pension and Other Postretirement Benefits Disclosure

Pensions and Other Postretirement Benefits

Defined Benefit Plans

The Company sponsors various defined benefit pension plans in several countries. Benefits provided generally depend on length of service, pay grade and remuneration levels. Employees in the U.S., Puerto Rico and certain international locations are also provided retirement benefits through defined contribution plans.

The Company also sponsors other postretirement benefit plans including plans that provide for postretirement supplemental medical coverage. Benefits from these plans are provided to employees and their spouses and dependents who meet various minimum age and service requirements. In addition, the Company sponsors other plans that provide for life insurance benefits and postretirement medical coverage for certain officers and management employees.

Net Periodic Benefit Cost

Components of net periodic benefit cost for the three months ended March 31, 2022 and 2021 were as follows:


		Pension and Other Postretirement Benefits
	Three Months Ended
	March 31,
(In millions)		2022		2021
Service cost		$	9.5	$	10.8
Interest cost		10.4		8.5
Expected return on plan assets		(16.6)		(16.5)
Amortization of prior service costs		0.1		(0.1)
Recognized net actuarial losses		—		0.3
Net periodic benefit cost		$	3.4	$	3.0

The Company is making the minimum mandatory contributions to its defined benefit pension plans in the U.S. and Puerto Rico for the 2022 plan year. The Company expects to make total benefit payments of approximately $118.0 million from pension and other postretirement benefit plans in 2022. The Company anticipates making contributions to pension and other postretirement benefit plans of approximately $52.0 million in 2022.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

Share-Based Incentive Plan (Stock Awards) (Details) - $ / shares	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 38.04	$ 37.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	(450,161)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	$ 27.54
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	5,077,897
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 38.21
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	4,831,333
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 39.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	5,126,329	5,576,490

Condensed Consolidated Statements Of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Net sales	$ 4,178.2	$ 4,400.1
Total revenues	4,191.7	4,430.3
Cost of sales	2,420.5	3,303.0
Gross profit	1,771.2	1,127.3
Operating expenses:
Research and development	142.3	184.1
Selling, general and administrative	915.3	1,186.5
Litigation settlements and other contingencies, net	6.2	22.9
Total operating expenses	1,063.8	1,393.5
Earnings (loss) from operations	707.4	(266.2)
Interest expense	146.2	169.0
Other expense, net	33.7	6.1
Earnings before income taxes	527.5	(441.3)
Income tax (benefit) provision	128.3	596.3
Net earnings (loss)	$ 399.2	$ (1,037.6)
Earnings (loss) per share attributable to Viatris Inc. shareholders
Basic (in USD per share)	$ 0.33	$ (0.86)
Diluted (in USD per share)	$ 0.33	$ (0.86)
Weighted average shares outstanding:
Basic	1,210.5	1,207.5
Diluted	1,213.1	1,207.5
Other Revenues
Weighted average shares outstanding:
Revenue Not from Contract with Customer	$ 13.5	$ 30.2

Income Taxes Income Taxes Disclosure (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Income Tax Contingency [Line Items]
Reserve for Uncertain Tax Positions, Including Interest And Penalties	$ 317.0	$ 315.6
Foreign Tax Authority \| Australian Taxation Office
Income Tax Contingency [Line Items]
Income Tax Examination, Partial Payment Of Income Tax Expense	$ 5.2	$ 56.0

Goodwill and Intangible Assets (Components of Intangible Assets) (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Intangible Assets by Major Class [Line Items]
Intangible asset impairment charges	$ 0.0	$ 83.4
Finite-lived intangible assets, original cost	38,550.7		$ 39,006.2
Finite-lived intangible assets, accumulated amortization	13,344.6		12,918.5
Finite-lived intangible assets, net book value	25,206.1		26,087.7
In-process research and development	45.7		46.5
Intangible assets, gross, excluding goodwill	38,596.4		39,052.7
Intangible assets, net book value, excluding goodwill	$ 25,251.8		$ 26,134.2
Patents and technologies
Intangible Assets by Major Class [Line Items]
Finite-lived intangible assets, estimated useful life, in years	15 years		15 years

Debt (Tables)

3 Months Ended

Mar. 31, 2022

Debt Disclosure [Abstract]

Summary of Long-Term Debt

A summary of long-term debt is as follows:


($ in millions)	Interest Rate as of March 31, 2022		March 31, 2022		December 31, 2021
Current portion of long-term debt:






2022 Euro Senior Notes ****	0.816	%	$	831.8	$	856.6
2022 Senior Notes ***	1.125	%	1,001.4		1,002.9
2023 Senior Notes (a) *	3.125	%	762.2		—
Other			0.9		0.9
Deferred financing fees			(0.9)		(0.1)
Current portion of long-term debt			$	2,595.4	$	1,860.3

Non-current portion of long-term debt:


2023 Senior Notes (a) *	3.125	%	—		766.1
2023 Senior Notes *	4.200	%	499.6		499.6
2024 Euro Senior Notes **	2.250	%	1,105.7		1,135.8
2024 Euro Senior Notes ****	1.023	%	846.5		871.6
2025 Euro Senior Notes *	2.125	%	552.7		567.8
2025 Senior Notes ***	1.650	%	762.4		763.4
2026 Senior Notes **	3.950	%	2,241.9		2,241.4
2027 Euro Senior Notes ****	1.362	%	984.0		1,013.0
2027 Senior Notes ***	2.300	%	779.4		780.8
2028 Euro Senior Notes **	3.125	%	825.0		847.4
2028 Senior Notes *	4.550	%	748.8		748.7
2030 Senior Notes ***	2.700	%	1,518.6		1,520.5
2032 Euro Senior Notes ****	1.908	%	1,502.8		1,546.6
2040 Senior Notes ***	3.850	%	1,655.4		1,657.1
2043 Senior Notes *	5.400	%	497.3		497.3
2046 Senior Notes **	5.250	%	999.9		999.9
2048 Senior Notes *	5.200	%	747.8		747.8
2050 Senior Notes ***	4.000	%	2,204.0		2,205.1
YEN Term Loan Facility			328.7		347.6
Other			1.9		1.9
Deferred financing fees			(39.9)		(42.3)
Long-term debt			$	18,762.5	$	19,717.1

____________

(a) In the first quarter of 2020, the Company terminated interest rate swaps designated as a fair value hedge resulting in net proceeds of approximately $45 million. The fair value adjustment is being amortized to interest expense over the remaining term of the notes.

* Instrument was issued by Mylan Inc.

** Instrument was originally issued by Mylan N.V.; now held by Utah Acquisition Sub Inc.

*** Instrument was issued by Viatris Inc.

**** Instrument was issued by Upjohn Finance B.V.

Minimum Repayments on Outstanding Borrowings

Mandatory minimum repayments remaining on the notional amount of outstanding long-term debt at March 31, 2022 were as follows for each of the periods ending December 31:


(In millions)	Total
2022	$	1,830
2023	1,250
2024	1,937
2025	1,303
2026	2,579
Thereafter	11,854
Total	$	20,753

Schedule of Short-term Debt

Short-Term Borrowings

The Company had $655.4 million and $1.49 billion of short-term borrowings as of March 31, 2022 and December 31, 2021, respectively.


(In millions)	March 31, 2022		December 31, 2021
Commercial paper notes	$	328.5	$	1,173.4
Receivables Facility	325.5		318.5

Other	1.4		1.1
Short-term borrowings	$	655.4	$	1,493.0

Balance Sheet Components (Trade Accounts Payable) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Accounts Payable, Current [Abstract]
Trade accounts payable	$ 928.4	$ 1,056.1
Other payables	571.2	601.3
Accounts payable	$ 1,499.6	$ 1,657.4

Financial Instruments and Risk Management (Financial Assets and Liabilities Carried at Fair Value) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	$ 48.0	$ 51.0
Fair value of financial instruments	202.8	144.6
Available-for-sale fixed income investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	36.6	38.2
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0.4	50.9
Equity securities	48.0	51.0
Total assets at recurring fair value measurement	48.4	101.9
Level 1 \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0.4	50.9
Level 1 \| Exchange traded funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	47.3	50.3
Level 1 \| Marketable securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0.7	0.7
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at recurring fair value measurement	239.4	182.8
Financial and Nonfinancial Liabilities, Fair Value Disclosure	98.9	61.0
Level 2 \| Foreign currency forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange derivative assets	202.8	144.6
Foreign exchange derivative liabilities	98.9	61.0
Level 2 \| Available-for-sale fixed income investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	36.6	38.2
Level 2 \| Corporate Bond Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	15.9	16.6
Level 2 \| U.S. Treasuries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	13.6	14.6
Level 2 \| Agency mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	2.5	2.0
Level 2 \| Asset-backed Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	4.1	4.6
Level 2 \| Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	0.5	0.4
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	198.4	199.7
Level 3 \| Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other Liabilities, Fair Value Disclosure	198.4
Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial instruments	$ 63.9	$ 62.0

Litigation (Other Litigation) (Narrative) (Details) $ in Millions	Mar. 31, 2022 USD ($)
Loss Contingencies [Line Items]
Number of cases	1,000
Other Litigation
Loss Contingencies [Line Items]
Loss Contingency Accrual	$ 34.8

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Tax Examinations The Company is subject to income taxes and tax audits in many jurisdictions. A certain degree of estimation is thus required in recording the assets and liabilities related to income taxes. Tax audits and examinations can involve complex issues, interpretations, and judgments and the resolution of matters that may span multiple years, particularly if subject to litigation or negotiation. Although the Company believes that adequate provisions have been made for these uncertain tax positions, the Company’s assessment of uncertain tax positions, including those arising from legal entity restructuring transactions in connection with the Combination, is based on estimates and assumptions that the Company believes are reasonable but the estimates for unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variations from such estimates could materially affect the Company’s financial condition, results of operations or cash flows in the period of resolution, settlement or when the statutes of limitations expire. The Company is subject to ongoing IRS examinations. The years 2015 through 2019 are open years under examination. The years 2012, 2013 and 2014 have one matter open, and a Tax Court petition was filed regarding the matter and a trial was held in December 2018 and is discussed further below. Several international audits are currently in progress. In some cases, the tax auditors have proposed adjustments or issued assessments to our tax positions, including with respect to intercompany transactions, and we are in ongoing discussions with some of the auditors regarding the validity of their positions. In instances where assessments have been issued, we disagree with these assessments and believe they are without merit and incorrect as a matter of law. As a result, we anticipate that certain of these matters may become the subject of litigation before tax courts where we intend to vigorously defend our position. In Australia, the tax authorities have issued notices of assessments to the Company for the years ended December 2009 to December 2020, subject to additional interest and penalties, concerning our tax position with respect to certain intercompany transactions. The tax authorities denied our objections to the assessments for the years ended December 2009 to December 2019 and we have commenced litigation in the Australian Federal Court challenging that decision. A decision on our objection to the assessment for the year ended December 2020 is pending. The Company made a partial payment of $56.0 million in 2021 and $5.2 million in 2022 in order to stay potential interest and penalties resulting from this litigation. In France, the tax authorities have issued notices of assessments to the Company for the years ended December 2013 to December 2015 concerning our tax position with respect to whether income earned by a Company entity not domiciled in France should be subject to French tax. We have commenced litigation before the French tax courts where the tax authorities will seek unpaid taxes, penalties, and interest. In India, the tax authorities have issued notices of assessments to the Company seeking unpaid taxes and interest for the financial years covering 2013 to 2018 concerning our tax position with respect to certain corporate tax deductions and certain intercompany transactions. Some of these assessments remain in the audit phase where we are challenging them before the tax authorities while we are challenging some of the other assessments in the Indian tax courts. The Company has recorded a net reserve for uncertain tax positions of $317.0 million and $315.6 million, including interest and penalties, in connection with its international audits at March 31, 2022 and December 31, 2021, respectively. In connection with our international tax audits, it is possible that we will incur material losses above the amounts reserved. The Company’s major U.S. state taxing jurisdictions remain open from fiscal year 2013 through 2020, with several state audits currently in progress. The Company’s major international taxing jurisdictions remain open from 2012 through 2020. Tax Court Proceedings The Company's U.S. federal income tax returns for 2012 through 2014 had been subject to proceedings in U.S. Tax Court involving a dispute with the IRS regarding whether certain costs related to ANDAs were eligible to be expensed and deducted immediately or required to be amortized over longer periods. A trial was held in U.S. Tax Court in December 2018 and on April 27, 2021, the Court affirmed Mylan’s position and held that patent litigation expenses related to ANDAs are immediately deductible. The IRS has appealed this decision. Accounting for Uncertainty in Income Taxes The impact of an uncertain tax position that is more likely than not of being sustained upon audit by the relevant taxing authority must be recognized at the largest amount that is more likely than not to be sustained. No portion of an uncertain tax position will be recognized if the position has less than a 50% likelihood of being sustained.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Revenue Recognition and Accounts Receivable

3 Months Ended

Mar. 31, 2022

Revenue from Contract with Customer [Abstract]

Revenue Recognition and Accounts Receivable

The Company recognizes revenues in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes net revenue for product sales when control of the promised goods or services is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Revenues are recorded net of provisions for variable consideration, including discounts, rebates, governmental rebate programs, price adjustments, returns, chargebacks, promotional programs and other sales allowances. Accruals for these provisions are presented in the condensed consolidated financial statements as reductions in determining net sales and as a contra asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash).

Our net sales may be impacted by wholesaler and distributor inventory levels of our products, which can fluctuate throughout the year due to the seasonality of certain products, pricing, the timing of product demand, purchasing decisions and other factors. Such fluctuations may impact the comparability of our net sales between periods.

Consideration received from licenses of intellectual property is recorded as other revenues. Royalty or profit share amounts, which are based on sales of licensed products or technology, are recorded when the customer’s subsequent sales or usages occur. Such consideration is included in other revenues in the condensed consolidated statements of operations.

The following table presents the Company’s net sales by product category for each of our reportable segments for the three months ended March 31, 2022 and 2021, respectively:


(In millions)	Three Months Ended March 31, 2022
Product Category	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Brands	$	1,298.7	$	569.7	$	249.0	$	436.7	$	2,554.1
Complex Gx and Biosimilars	364.1		—		10.3		16.4		390.8
Generics	813.3		3.4		164.5		252.1		1,233.3
Total	$	2,476.1	$	573.1	$	423.8	$	705.2	$	4,178.2


(In millions)	Three Months Ended March 31, 2021
Product Category	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Brands	$	1,403.7	$	590.9	$	284.0	$	446.0	$	2,724.6
Complex Gx and Biosimilars	312.0		—		8.9		8.0		328.9
Generics	855.9		1.0		189.0		300.7		1,346.6
Total	$	2,571.6	$	591.9	$	481.9	$	754.7	$	4,400.1

The following table presents net sales on a consolidated basis for select key products for the three months ended March 31, 2022 and 2021:


	Three months ended March 31,
(In millions)	2022		2021

Select Key Global Products
Lipitor ®	$	440.1	$	464.6
Norvasc ®	207.8		227.7
Lyrica ®	171.7		187.8
Viagra ®	129.8		139.6
EpiPen® Auto-Injectors	88.8		103.7
Celebrex ®	85.2		89.0
Effexor ®	77.5		76.6
Creon ®	74.7		69.9
Zoloft ®	73.1		76.6
Xalabrands	53.0		57.9

Select Key Segment Products

Dymista ®	$	44.0	$	40.3
Yupelri ®	43.7		36.9
Amitiza ®	41.8		45.9
Xanax ®	40.0		45.1

____________

(a)The Company does not disclose net sales for any products considered competitively sensitive.

(b)Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches.

(c)Amounts for the three months ended March 31, 2022 include the unfavorable impact of foreign currency translations compared to the prior year period.

Variable Consideration and Accounts Receivable

The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the three months ended March 31, 2022 and 2021, respectively:


	Three Months Ended
	March 31,
(In millions)		2022		2021
Gross sales		$	7,198.3	$	7,567.0
Gross to net adjustments:
Chargebacks		(1,584.2)		(1,318.0)
Rebates, promotional programs and other sales allowances		(1,205.9)		(1,568.5)
Returns		(82.6)		(113.0)
Governmental rebate programs		(147.4)		(167.4)
Total gross to net adjustments		$	(3,020.1)	$	(3,166.9)
Net sales		$	4,178.2	$	4,400.1

No significant revisions were made to the methodology used in determining these provisions or the nature of the provisions during the three months ended March 31, 2022. Such allowances were comprised of the following at March 31, 2022 and December 31, 2021, respectively:


(In millions)	March 31, 2022		December 31, 2021
Accounts receivable, net	$	1,707.1	$	1,688.6
Other current liabilities	1,095.8		1,362.1
Total	$	2,802.9	$	3,050.7

Accounts receivable, net was comprised of the following at March 31, 2022 and December 31, 2021, respectively:


(In millions)	March 31, 2022		December 31, 2021
Trade receivables, net	$	3,556.9	$	3,774.4
Other receivables	537.0		492.0
Accounts receivable, net	$	4,093.9	$	4,266.4

Accounts Receivable Factoring Arrangements

We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $55.1 million and $29.6 million of accounts receivable as of March 31, 2022 and December 31, 2021, respectively, under these factoring arrangements.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

+ Details

Recent Accounting Pronouncements Recent Accounting Pronouncements (Impact of Adoption - ASU 2014-09) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cost of sales	$ 2,420.5	$ 3,303.0
Income tax (benefit) provision	128.3	596.3
Net earnings (loss) attributable to Viatris Inc. common shareholders	399.2	(1,037.6)
Revenues	4,191.7	$ 4,430.3
Prepaid expenses and other current assets	1,763.6		$ 1,957.6
Income taxes payable	177.8		236.9
Retained earnings	3,941.5		3,688.8
Accumulated other comprehensive loss	$ (2,061.0)		$ (1,744.3)

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References + Details

- Definition

+ References

+ Details

Share-Based Incentive Plan

3 Months Ended

Mar. 31, 2022

Share-based Payment Arrangement [Abstract]

Share-Based Incentive Plan

Prior to the Distribution, Viatris adopted and Pfizer, in the capacity as Viatris’ sole stockholder at such time, approved the Plan which became effective as of the Distribution. In connection with the Combination, as of November 16, 2020, the Company assumed the 2003 LTIP, which had previously been approved by Mylan shareholders. The Plan and 2003 LTIP include (i) 72,500,000 shares of common stock authorized for grant pursuant to the Plan, which may include dividend payments payable in common stock on unvested shares granted under awards, (ii) 6,757,640 shares of common stock to be issued pursuant to the exercise of outstanding stock options granted to participants under the 2003 LTIP and assumed by Viatris in connection with the Combination and (iii) 13,535,627 shares of common stock subject to outstanding equity-based awards, other than stock options, assumed by Viatris in connection with the Combination, or that otherwise remain available for issuance under the 2003 LTIP.

Under the Plan and 2003 LTIP, shares are reserved for issuance to key employees, consultants, independent contractors and non-employee directors of the Company through a variety of incentive awards, including: stock options, SARs, restricted stock and units, PSUs, other stock-based awards and short-term cash awards. Stock option awards are granted with an exercise price equal to the fair market value of the shares underlying the stock options at the date of the grant, generally become exercisable over periods ranging from three to four years, and generally expire in ten years.

The following table summarizes stock awards (stock options and SARs) activity under the Plan and 2003 LTIP:


	Number of Shares Under Stock Awards	Weighted Average Exercise Price per Share
Outstanding at December 31, 2021	5,576,490	$	37.19


Forfeited	(450,161)	$	27.54
Outstanding at March 31, 2022	5,126,329	$	38.04
Vested and expected to vest at March 31, 2022	5,077,897	$	38.21
Exercisable at March 31, 2022	4,831,333	$	39.19

As of March 31, 2022, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable had average remaining contractual terms of 4.7 years, 4.6 years and 4.5 years, respectively. Also, at March 31, 2022, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable had no aggregate intrinsic value.

A summary of the status of the Company’s nonvested restricted stock awards (restricted stock and restricted stock unit awards, including PSUs) as of March 31, 2022 and the changes during the three months ended March 31, 2022 are presented below:


	Number of Restricted Stock Awards	Weighted Average Grant-Date Fair Value Per Share
Nonvested at December 31, 2021	16,858,128	$	15.12
Granted	16,635,392	10.20
Released	(3,517,219)	17.95
Forfeited	(229,241)	13.99
Nonvested at March 31, 2022	29,747,060	$	12.04

As of March 31, 2022, the Company had $272.7 million of total unrecognized compensation expense, net of estimated forfeitures, related to all of its stock-based awards, which we expect to recognize over the remaining weighted average vesting period of 2.0 years. The total intrinsic value of restricted stock units released during the three months ended March 31, 2022 and 2021 was $63.1 million and $30.8 million, respectively.

Earnings (Loss) per Ordinary Share (Basic and Diluted Earnings Per Ordinary Share) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share [Abstract]
Net earnings (loss) attributable to Viatris Inc. common shareholders	$ 399.2	$ (1,037.6)
Weighted average shares outstanding	1,210.5	1,207.5
Weighted average number diluted shares outstanding adjustment, stock-based awards and warrants	2.6	0.0
Total dilutive shares outstanding	1,213.1	1,207.5
Basic earnings (loss) per share attributable to Viatris Inc. shareholders	$ 0.33	$ (0.86)
Diluted earnings (loss) per ordinary share	$ 0.33	$ (0.86)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

+ Details

Pensions and Other Postretirement Benefits (Net Periodic Benefit Costs) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Pension and other postretirement benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 9.5	$ 10.8
Interest cost	10.4	8.5
Expected return on plan assets	(16.6)	(16.5)
Amortization of prior service costs	0.1	(0.1)
Recognized net actuarial losses	0.0	0.3
Net periodic benefit cost	3.4	3.0
Defined Benefit Plan Items \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Defined Benefit Plan Disclosure [Line Items]
Amortization of prior service costs		$ 0.1
Defined Benefit Plan Items \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Pension and other postretirement benefits
Defined Benefit Plan Disclosure [Line Items]
Amortization of prior service costs	$ 0.1

Revenue Recognition and Accounts Receivable (Tables)

3 Months Ended

Mar. 31, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following table presents the Company’s net sales by product category for each of our reportable segments for the three months ended March 31, 2022 and 2021, respectively:


(In millions)	Three Months Ended March 31, 2022
Product Category	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Brands	$	1,298.7	$	569.7	$	249.0	$	436.7	$	2,554.1
Complex Gx and Biosimilars	364.1		—		10.3		16.4		390.8
Generics	813.3		3.4		164.5		252.1		1,233.3
Total	$	2,476.1	$	573.1	$	423.8	$	705.2	$	4,178.2


(In millions)	Three Months Ended March 31, 2021
Product Category	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Brands	$	1,403.7	$	590.9	$	284.0	$	446.0	$	2,724.6
Complex Gx and Biosimilars	312.0		—		8.9		8.0		328.9
Generics	855.9		1.0		189.0		300.7		1,346.6
Total	$	2,571.6	$	591.9	$	481.9	$	754.7	$	4,400.1

The following table presents net sales on a consolidated basis for select key products for the three months ended March 31, 2022 and 2021:


	Three months ended March 31,
(In millions)	2022		2021

Select Key Global Products
Lipitor ®	$	440.1	$	464.6
Norvasc ®	207.8		227.7
Lyrica ®	171.7		187.8
Viagra ®	129.8		139.6
EpiPen® Auto-Injectors	88.8		103.7
Celebrex ®	85.2		89.0
Effexor ®	77.5		76.6
Creon ®	74.7		69.9
Zoloft ®	73.1		76.6
Xalabrands	53.0		57.9

Select Key Segment Products

Dymista ®	$	44.0	$	40.3
Yupelri ®	43.7		36.9
Amitiza ®	41.8		45.9
Xanax ®	40.0		45.1

____________

(a)The Company does not disclose net sales for any products considered competitively sensitive.

(b)Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches.

(c)Amounts for the three months ended March 31, 2022 include the unfavorable impact of foreign currency translations compared to the prior year period.

Variable Consideration and Accounts Receivable

The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the three months ended March 31, 2022 and 2021, respectively:


	Three Months Ended
	March 31,
(In millions)		2022		2021
Gross sales		$	7,198.3	$	7,567.0
Gross to net adjustments:
Chargebacks		(1,584.2)		(1,318.0)
Rebates, promotional programs and other sales allowances		(1,205.9)		(1,568.5)
Returns		(82.6)		(113.0)
Governmental rebate programs		(147.4)		(167.4)
Total gross to net adjustments		$	(3,020.1)	$	(3,166.9)
Net sales		$	4,178.2	$	4,400.1

Schedule of Accounts Receivable, Net

Such allowances were comprised of the following at March 31, 2022 and December 31, 2021, respectively:


(In millions)	March 31, 2022		December 31, 2021
Accounts receivable, net	$	1,707.1	$	1,688.6
Other current liabilities	1,095.8		1,362.1
Total	$	2,802.9	$	3,050.7

Accounts receivable, net was comprised of the following at March 31, 2022 and December 31, 2021, respectively:


(In millions)	March 31, 2022		December 31, 2021
Trade receivables, net	$	3,556.9	$	3,774.4
Other receivables	537.0		492.0
Accounts receivable, net	$	4,093.9	$	4,266.4

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net earnings (loss) attributable to Viatris Inc. common shareholders	$ 399.2	$ (1,037.6)
Adjustments to reconcile net earnings (loss) to net cash provided by operating activities:
Depreciation and amortization	736.0	1,422.5
Share-based Compensation	28.3	32.7
Deferred income tax (benefit) expense	(52.8)	288.4
Loss from equity method investments	(0.1)	17.9
Other non-cash items	37.8	33.3
Litigation settlements and other contingencies, net	5.2	22.9
Changes in operating assets and liabilities:
Accounts receivable	(115.5)	(59.8)
Inventories	(69.1)	(203.4)
Accounts payable	(30.2)	191.9
Income taxes	67.0	494.6
Other operating assets and liabilities, net	132.7	(354.6)
Net cash provided by operating activities	1,138.5	848.8
Cash flows from investing activities:
Cash paid for acquisitions, net	0.0	277.0
Capital expenditures	(64.5)	(49.5)
Purchase of marketable securities	(8.6)	(12.3)
Proceeds from the sale of marketable securities	8.5	12.3
Payments for product rights and other, net	(7.4)	(3.7)
Proceeds from the sale of assets	5.1	12.5
Net cash used in investing activities	(66.9)	236.3
Cash flows from financing activities:
Proceeds from issuance of long-term debt	0.1	0.0
Payments of long-term debt	(0.1)	0.0
Change in short-term borrowings, net	(837.9)	(1,063.9)
Taxes paid related to net share settlement of equity awards	(9.9)	(7.8)
Contingent consideration payments	(15.5)	(26.0)
Payments of financing fees	(0.4)	0.0
Other items, net	(0.2)	(2.1)
Net cash used in financing activities	(1,009.0)	(1,099.8)
Effect on cash of changes in exchange rates	(11.4)	(22.2)
Net increase (decrease) in cash, cash equivalents and restricted cash	51.2	(36.9)
Cash, cash equivalents and restricted cash — beginning of period	706.2	850.0
Cash, cash equivalents and restricted cash — end of period	757.4	813.1
Payments to Noncontrolling Interests	$ (145.1)	$ 0.0

Balance Sheet Components

3 Months Ended

Mar. 31, 2022

Balance Sheet Components [Abstract]

Balance Sheet Components

Selected balance sheet components consist of the following:

Cash and restricted cash


(In millions)	March 31, 2022		December 31, 2021		March 31, 2021
Cash and cash equivalents	$	752.4	$	701.2	$	806.9
Restricted cash, included in prepaid expenses and other current assets	5.0		5.0		6.2
Cash, cash equivalents and restricted cash	$	757.4	$	706.2	$	813.1

Inventories


(In millions)	March 31, 2022		December 31, 2021
Raw materials	$	868.1	$	922.4
Work in process	767.5		993.3
Finished goods	2,161.7		2,062.0
Inventories	$	3,797.3	$	3,977.7

Prepaid expenses and other current assets


(In millions)	March 31, 2022		December 31, 2021
Prepaid expenses	$	268.1	$	256.7

Available-for-sale fixed income securities	36.6		38.2
Fair value of financial instruments	202.8		144.6
Equity securities	48.0		51.0
Other current assets	1,208.1		1,467.1
Prepaid expenses and other current assets	$	1,763.6	$	1,957.6

Prepaid expenses consist primarily of prepaid rent, insurance and other individually insignificant items.

Property, plant and equipment, net


(In millions)	March 31, 2022		December 31, 2021
Machinery and equipment	$	2,845.8	$	3,054.0
Buildings and improvements	1,578.4		1,808.5
Construction in progress	541.8		588.7
Land and improvements	126.5		137.9
Gross property, plant and equipment	5,092.5		5,589.1
Accumulated depreciation	1,942.3		2,400.5
Property, plant and equipment, net	$	3,150.2	$	3,188.6

Other assets


(In millions)	March 31, 2022		December 31, 2021

Operating lease right-of-use assets	$	281.7	$	290.8
Other long-term assets	774.3		879.9
Other assets	$	1,056.0	$	1,170.7

Accounts payable


(In millions)	March 31, 2022		December 31, 2021
Trade accounts payable	$	928.4	$	1,056.1
Other payables	571.2		601.3
Accounts payable	$	1,499.6	$	1,657.4

Other current liabilities


(In millions)	March 31, 2022		December 31, 2021
Accrued sales allowances	$	1,095.8	$	1,362.1
Legal and professional accruals, including litigation accruals	694.9		715.6
Payroll and employee benefit liabilities	567.1		741.9
Contingent consideration	86.2		66.7
Accrued restructuring	171.8		233.5
Accrued interest	228.8		86.6

Equity method investments, clean energy investments	4.3		10.9
Fair value of financial instruments	98.9		61.0
Operating lease liability	89.9		86.7
Other	1,388.6		1,254.6
Other current liabilities	$	4,426.3	$	4,619.6

Other long-term obligations


(In millions)	March 31, 2022		December 31, 2021
Employee benefit liabilities	$	861.3	$	876.4
Contingent consideration	112.2		133.0

Tax related items, including contingencies	429.5		426.1
Operating lease liability	191.7		200.9
Accrued restructuring	51.4		64.3
Other	238.2		232.9
Other long-term obligations	$	1,884.3	$	1,933.6

Balance Sheet Components (Prepaid Expenses and Other Current Assets) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Prepaid expenses	$ 268.1	$ 256.7
Fair value of financial instruments	202.8	144.6
Equity securities	48.0	51.0
Other current assets	1,208.1	1,467.1
Prepaid expenses and other current assets	1,763.6	1,957.6
Available-for-sale fixed income investments
Property, Plant and Equipment [Line Items]
Available-for-sale securities	$ 36.6	$ 38.2

Balance Sheet Components (Other Current Liabilities) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Schedule of other current liabilities [Line Items]
Other receivables	$ 537.0	$ 492.0
Legal and professional accruals, including litigation accruals	694.9	715.6
Payroll and employee benefit liabilities	567.1	741.9
Contingent consideration	198.4	199.7
Restructuring	171.8	233.5
Accrued interest	228.8	86.6
Equity method investments, clean energy investments	4,426.3	4,619.6
Fair value of financial instruments	98.9	61.0
Operating lease liability	89.9	86.7
Other	1,388.6	1,254.6
Clean energy investments
Schedule of other current liabilities [Line Items]
Equity method investments, clean energy investments	4.3	10.9
Other Current Liabilities [Member]
Schedule of other current liabilities [Line Items]
Contingent consideration	86.2	66.7
Variable Consideration
Schedule of other current liabilities [Line Items]
Other receivables	$ 1,095.8	$ 1,362.1

Litigation (Drug Pricing Matters) (Details) - Mar. 31, 2022	Total	state
Multi District Litigation [Member]
Loss Contingencies [Line Items]
Number of states	46	46
Anticompetitive Conduct with Doxycycline Hyclate Delayed Release, Doxycycline Monohydrate, Glipizide-Metformin and Verapamil [Member]
Loss Contingencies [Line Items]
Number of states	36
Anticompetitive Conduct with Generic Drugs [Member]
Loss Contingencies [Line Items]
Number of states	47
Amended Anticompetitive Conduct with Generic Drugs [Member]
Loss Contingencies [Line Items]
Number of states	42

Financial Instruments and Risk Management (Effect Of Derivative Instruments on the Condensed Consolidated Statements of Operations Derivatives in Fair Value Hedging Relationships) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Fair Value Hedges Recognized in Earnings	$ 21.7	$ 35.6

Debt (Receivables, Securitization Facility and Commercial Paper) (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Short-term Debt [Line Items]
Short-term borrowings	$ 655,400,000	$ 1,493,000,000
Commercial Paper [Member]
Short-term Debt [Line Items]
Short-term borrowings	328,500,000	1,173,400,000
Receivables Facility
Short-term Debt [Line Items]
Short-term borrowings	325,500,000	318,500,000
Other Current Portion of Long-term Debt
Short-term Debt [Line Items]
Short-term borrowings	1,400,000	$ 1,100,000
Receivables Facility \| Revolving Credit Facility
Short-term Debt [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 400,000,000

Earnings (Loss) per Ordinary Share

3 Months Ended

Mar. 31, 2022

Earnings Per Share [Abstract]

Earnings (Loss) per Ordinary Share

Earnings (Loss) per Share

Basic earnings (loss) per share is computed by dividing net earnings (loss) by the weighted average number of shares outstanding during the period. Diluted earnings (loss) per share is computed by dividing net earnings (loss) by the weighted average number of shares outstanding during the period increased by the number of additional shares that would have been outstanding related to potentially dilutive securities or instruments, if the impact is dilutive.

Basic and diluted earnings (loss) per share attributable to Viatris Inc. are calculated as follows:


	Three Months Ended
	March 31,
(In millions, except per share amounts)		2022		2021
Basic earnings (loss) attributable to Viatris Inc. common shareholders
Net earnings (loss) attributable to Viatris Inc. common shareholders		$	399.2	$	(1,037.6)
Shares (denominator):
Weighted average shares outstanding		1,210.5		1,207.5
Basic earnings (loss) per share attributable to Viatris Inc. shareholders		$	0.33	$	(0.86)

Diluted earnings (loss) attributable to Viatris Inc. common shareholders
Net earnings (loss) attributable to Viatris Inc. common shareholders		$	399.2	$	(1,037.6)
Shares (denominator):
Weighted average shares outstanding		1,210.5		1,207.5
Share-based awards		2.6		—
Total dilutive shares outstanding		1,213.1		1,207.5
Diluted earnings (loss) per share attributable to Viatris Inc. shareholders		$	0.33	$	(0.86)

Additional stock awards and restricted stock awards were outstanding during the three months ended March 31, 2022 and 2021, but were not included in the computation of diluted earnings per share for each respective period because the effect would be anti-dilutive. Excluded shares at March 31, 2022 include certain share-based compensation awards whose performance conditions had not been fully met. Such excluded shares and anti-dilutive awards represented 15.5 million shares and 10.9 million shares for the three months ended March 31, 2022 and 2021, respectively.

The Company paid a quarterly dividend of $0.12 per share on the Company’s issued and outstanding common stock on March 16, 2022. On May 5, 2022, the Company’s Board of Directors declared a quarterly cash dividend of $0.12 per share on the Company’s issued and outstanding common stock, which will be payable on June 16, 2022 to shareholders of record as of the close of business on May 24, 2022. The declaration and payment of future dividends to holders of the Company’s common stock will be at the discretion of the Board of Directors, and will depend upon factors, including but not limited to, the Company’s financial condition, earnings, capital requirements of its businesses, legal requirements, regulatory constraints, industry practice, and other factors that the Board of Directors deems relevant.

On May 6, 2022, the Company announced that its Board of Directors had authorized a DRIP. The DRIP will allow shareholders to automatically reinvest all or a portion of the cash dividends paid on their shares of the Company’s common stock and to make certain additional optional cash investments in the Company’s common stock.

On February 28, 2022, the Company announced that its Board of Directors had authorized a share repurchase program for the repurchase of up to $1.0 billion of the Company’s shares of common stock. The Company has not yet repurchased any shares of common stock under the share repurchase program and the share repurchase program does not obligate the Company to acquire any particular amount of common stock.

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Balance Sheets Fair Value of Derivative Instruments Derivatives Designated As Hedging Instruments) (Details) - USD ($)
$ in Millions

3 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Derivatives, Fair Value [Line Items]

Fair value of financial instruments

$ 202.8

$ 144.6

Fair value of financial instruments

$ 98.9

61.0

Designated as Hedging Instrument

Derivatives, Fair Value [Line Items]

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value

The following table summarizes the classification and fair values of derivative instruments in our condensed consolidated balance sheets:


	Asset Derivatives					Liability Derivatives
(In millions)	Balance Sheet Location	March 31, 2022 Fair Value		December 31, 2021 Fair Value		Balance Sheet Location	March 31, 2022 Fair Value		December 31, 2021 Fair Value

Derivatives designated as hedges:

Foreign currency forward contracts	Prepaid expenses & other current assets	$	63.9	$	62.0	Other current liabilities	$	7.6	$	4.3
Total derivatives designated as hedges		63.9		62.0			7.6		4.3
Derivatives not designated as hedges:
Foreign currency forward contracts	Prepaid expenses & other current assets	138.9		82.6		Other current liabilities	91.3		56.7
Total derivatives not designated as hedges		138.9		82.6			91.3		56.7
Total derivatives		$	202.8	$	144.6		$	98.9	$	61.0

Fair value of financial instruments

$ 63.9

62.0

Fair value of financial instruments

7.6

4.3

Designated as Hedging Instrument | Prepaid expenses and other current assets | Foreign exchange forward contracts

Derivatives, Fair Value [Line Items]

Fair value of financial instruments

63.9

62.0

Designated as Hedging Instrument | Other Current Liabilities [Member] | Foreign exchange forward contracts

Derivatives, Fair Value [Line Items]

Fair value of financial instruments

7.6

4.3

Not Designated as Hedging Instruments

Derivatives, Fair Value [Line Items]

Fair value of financial instruments

138.9

82.6

Fair value of financial instruments

91.3

56.7

Not Designated as Hedging Instruments | Prepaid expenses and other current assets | Foreign currency forward contracts

Derivatives, Fair Value [Line Items]

Fair value of financial instruments

138.9

82.6

Not Designated as Hedging Instruments | Other Current Liabilities [Member] | Foreign currency forward contracts

Derivatives, Fair Value [Line Items]

Fair value of financial instruments

$ 91.3

$ 56.7

Recent Accounting Pronouncements	3 Months Ended
Recent Accounting Pronouncements	Mar. 31, 2022
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements	Recent Accounting Pronouncements Adoption of New Accounting Standard In November 2021, the FASB issued Accounting Standards Update 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance (“ASU 2021-10”), which requires entities to provide annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. We adopted the ASU prospectively on January 1, 2022. The additional annual disclosures required are not expected to have a material impact on our consolidated financial statements. There were no other significant changes in new accounting standards from those disclosed in Viatris’ 2021 Form 10-K. Refer to Viatris’ 2021 Form 10-K for additional information.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (c)

+ Details

Debt (Summary of Long-Term Debt) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Current portion of long-term debt	$ 2,595.4	$ 1,860.3
Unamortized debt issuance expense	(39.9)	(42.3)
Long-term debt	18,762.5	19,717.1
Proceeds from sale of terminated interest rate swaps	45.0
Other Current Portion of Long-term Debt
Debt Instrument [Line Items]
Current portion of long-term debt	$ 0.9	0.9
2020 Euro Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	0.816%
Current portion of long-term debt	$ 831.8	856.6
Long-term debt	$ 328.7	347.6
2020 Senior Notes (3.750% coupon)
Debt Instrument [Line Items]
Stated percentage rate	1.125%
Current portion of long-term debt	$ 1,001.4	1,002.9
2023 Senior Notes (3.125% coupon)
Debt Instrument [Line Items]
Stated percentage rate	3.125%
Current portion of long-term debt	$ 762.2	0.0
Other
Debt Instrument [Line Items]
Long-term debt	$ 1.9	1.9
2024 Euro Senior Notes, 1.023%
Debt Instrument [Line Items]
Stated percentage rate	1.023%
2027 Euro Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	1.362%
2027 Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	2.30%
Senior Notes \| 2023 Senior Notes (3.125% coupon)
Debt Instrument [Line Items]
Stated percentage rate	3.125%
Long-term debt	$ 0.0	766.1
Senior Notes \| 2023 Senior Notes (4.200% coupon)
Debt Instrument [Line Items]
Stated percentage rate	4.20%
Long-term debt	$ 499.6	499.6
Senior Notes \| 2024 Euro Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	2.25%
Long-term debt	$ 1,105.7	1,135.8
Senior Notes \| 2.125% Euro Senior Notes due 2025
Debt Instrument [Line Items]
Stated percentage rate	2.125%
Long-term debt	$ 552.7	567.8
Senior Notes \| 2026 Senior Notes (3.950% coupon)
Debt Instrument [Line Items]
Stated percentage rate	3.95%
Long-term debt	$ 2,241.9	2,241.4
Senior Notes \| 2028 Euro Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	3.125%
Long-term debt	$ 825.0	847.4
Senior Notes \| SeniorNotesTwoThousandTwentyEight [Member]
Debt Instrument [Line Items]
Stated percentage rate	4.55%
Senior Notes \| 2028 Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt	$ 748.8	748.7
Senior Notes \| 2043 Senior Notes (5.400% coupon)
Debt Instrument [Line Items]
Stated percentage rate	5.40%
Long-term debt	$ 497.3	497.3
Senior Notes \| 2046 Senior Notes (5.250% coupon)
Debt Instrument [Line Items]
Stated percentage rate	5.25%
Long-term debt	$ 999.9	999.9
Senior Notes \| 2048 Senior Notes (5.200%)
Debt Instrument [Line Items]
Stated percentage rate	5.20%
Senior Notes \| 2048 Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt	$ 747.8	747.8
Senior Notes \| 2024 Euro Senior Notes, 1.023%
Debt Instrument [Line Items]
Long-term debt	$ 846.5	871.6
Senior Notes \| 2025 Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	1.65%
Long-term debt	$ 762.4	763.4
Senior Notes \| 2027 Euro Senior Notes
Debt Instrument [Line Items]
Long-term debt	984.0	1,013.0
Senior Notes \| 2027 Senior Notes
Debt Instrument [Line Items]
Long-term debt	$ 779.4	780.8
Senior Notes \| 2030 Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	2.70%
Long-term debt	$ 1,518.6	1,520.5
Senior Notes \| 2032 Euro Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	1.908%
Long-term debt	$ 1,502.8	1,546.6
Senior Notes \| 2040 Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	3.85%
Long-term debt	$ 1,655.4	1,657.1
Senior Notes \| 2050 Senior Notes
Debt Instrument [Line Items]
Stated percentage rate	4.00%
Long-term debt	$ 2,204.0	2,205.1
Current Portion of Long-Term Debt
Debt Instrument [Line Items]
Unamortized debt issuance expense	$ (0.9)	$ (0.1)

Balance Sheet Components (Inventories) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Balance Sheet Components [Abstract]
Raw materials	$ 868.1	$ 922.4
Work in process	767.5	993.3
Finished goods	2,161.7	2,062.0
Inventories	$ 3,797.3	$ 3,977.7

Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($)
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	$ 199.7
Payments	15.5
Reclassifications	0.0
Accretion expense	1.9
Fair value loss	12.3
Balance at end of period	198.4
Other Current Liabilities [Member]
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	66.7
Payments	15.5
Reclassifications	35.0
Accretion expense	0.0
Fair value loss	0.0
Balance at end of period	86.2
Other long-term obligations
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	133.0
Payments	0.0
Reclassifications	(35.0)
Accretion expense	1.9
Fair value loss	12.3
Balance at end of period	$ 112.2

Share-Based Incentive Plan (Nonvested Restricted Stock, Restricted Stock Units and PSUs Activity) (Details) - Restricted stock awards	3 Months Ended
	Mar. 31, 2022 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of restricted stock awards, nonvested beginning of period \| shares	16,858,128
Weighted average grant-date fair value per share, nonvested beginning of period \| $ / shares	$ 15.12
Number of restricted stock awards, granted \| shares	16,635,392
Weighted average grant-date fair value per share, granted \| $ / shares	$ 10.20
Number of restricted stock awards, released \| shares	(3,517,219)
Weighted average grant-date fair value per share, released \| $ / shares	$ 17.95
Number of restricted stock awards, forfeited \| shares	(229,241)
Weighted average grant-date fair value per share, forfeited \| $ / shares	$ 13.99
Number of restricted stock awards, nonvested end of period \| shares	29,747,060
Weighted average grant-date fair value per share, nonvested end of period \| $ / shares	$ 12.04

Share-Based Incentive Plan (Tables)

3 Months Ended

Mar. 31, 2022

Share-based Payment Arrangement [Abstract]

Stock Awards Activity

The following table summarizes stock awards (stock options and SARs) activity under the Plan and 2003 LTIP:


	Number of Shares Under Stock Awards	Weighted Average Exercise Price per Share
Outstanding at December 31, 2021	5,576,490	$	37.19


Forfeited	(450,161)	$	27.54
Outstanding at March 31, 2022	5,126,329	$	38.04
Vested and expected to vest at March 31, 2022	5,077,897	$	38.21
Exercisable at March 31, 2022	4,831,333	$	39.19

Nonvested Restricted Stock and Restricted Stock Unit Awards Activity


	Number of Restricted Stock Awards	Weighted Average Grant-Date Fair Value Per Share
Nonvested at December 31, 2021	16,858,128	$	15.12
Granted	16,635,392	10.20
Released	(3,517,219)	17.95
Forfeited	(229,241)	13.99
Nonvested at March 31, 2022	29,747,060	$	12.04

Balance Sheet Components - Assets and Liabilities Held For Sale (Details) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue of biosimilars portfolio		$ 169.1
Liabilities held for sale		277.7	$ 0.0
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations \| Biocon Biologics \| Biosimilars Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, net		136.1
Inventories		122.4
Prepaid expenses and other current assets		12.5
Intangible assets, net		7.5
Goodwill		953.0
Other assets		105.6
Accounts payable		95.4
Accounts payable		$ 182.3
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations \| Scenario, Forecast \| Biocon Biologics \| Biosimilars Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Upfront payment subject to certain adjustments	$ 2,000.0
Percent ownership after transaction	12.90%
Additional cash payments to be received	$ 335.0
Term of transition services agreement	2 years

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Balance Sheets Fair Values of Derivative Instruments Derivatives Not Designated As Hedging Instrument) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	$ 202.8	$ 144.6
Fair value of financial instruments	98.9	61.0
Not Designated as Hedging Instruments
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	138.9	82.6
Fair value of financial instruments	91.3	56.7
Not Designated as Hedging Instruments \| Prepaid expenses and other current assets \| Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	138.9	82.6
Not Designated as Hedging Instruments \| Other current liabilities \| Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	$ 91.3	$ 56.7

Restructuring

3 Months Ended

Mar. 31, 2022

Restructuring and Related Activities [Abstract]

Restructuring

2020 Restructuring Program

During the fourth quarter of 2020, Viatris announced a significant global restructuring program in order to achieve synergies and ensure that the organization is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers, and other stakeholders. As part of the restructuring, the Company is optimizing its commercial capabilities and enabling functions, and closing, downsizing or divesting certain manufacturing facilities globally that are deemed to be no longer viable either due to surplus capacity, challenging market dynamics or a shift in its product portfolio toward more complex products.

For the committed restructuring actions, the Company expects to incur total pre-tax charges of up to approximately $1.4 billion. Such charges are expected to include up to approximately $450 million of non-cash charges mainly related to accelerated depreciation and asset impairment charges, including inventory write-offs. The remaining estimated cash costs of up to approximately $950 million are expected to be primarily related to severance and employee benefits expense, as well as other costs, including those related to contract terminations and other plant disposal costs.

Charges for restructuring and ongoing cost reduction initiatives are recorded in the period the Company commits to a restructuring or cost reduction plan, or executes specific actions contemplated by the plan and all criteria for liability recognition have been met.

The following table summarizes the restructuring charges and the reserve activity for the 2020 restructuring program from December 31, 2021 to March 31, 2022:


(In millions)	Employee Related Costs		Other Exit Costs		Total
Balance at December 31, 2021:	$	292.6	$	4.1	$	296.7
Charges (1)	7.3		9.5		16.8

Cash payment	(77.6)		(6.2)		(83.8)
Utilization	—		(4.2)		(4.2)
Foreign currency translation	(2.1)		(0.1)		(2.2)
Balance at March 31, 2022:	$	220.2	$	3.1	$	223.3

____________

At March 31, 2022 and December 31, 2021, accrued liabilities for restructuring and other cost reduction programs were primarily included in other current liabilities and other long-term obligations in the condensed consolidated balance sheets.

Financial Instruments and Risk Management (Tables)

3 Months Ended

Mar. 31, 2022

Derivatives, Fair Value [Line Items]

Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]

A rollforward of the activity in the Company’s fair value of contingent consideration from December 31, 2021 to March 31, 2022 is as follows:


(In millions)	Current Portion (1)		Long-Term Portion (2)		Total Contingent Consideration
Balance at December 31, 2021	$	66.7	$	133.0	$	199.7
Payments	(15.5)		—		(15.5)
Reclassifications	35.0		(35.0)		—
Accretion	—		1.9		1.9
Fair value loss (3)	—		12.3		12.3
Balance at March 31, 2022	$	86.2	$	112.2	$	198.4

____________

(1)Included in other current liabilities in the condensed consolidated balance sheets.

(2)Included in other long-term obligations in the condensed consolidated balance sheets.

(3)Included in litigation settlements and other contingencies, net in the condensed consolidated statements of operations.

Financial Assets and Liabilities Carried at Fair Value

Financial assets and liabilities carried at fair value are classified in the tables below in one of the three categories described above:


	March 31, 2022						December 31, 2021
(In millions)	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Recurring fair value measurements
Financial Assets
Cash equivalents:
Money market funds	$	0.4	$	—	$	—	$	50.9	$	—	$	—
Total cash equivalents	0.4		—		—		50.9		—		—
Equity securities:
Exchange traded funds	47.3		—		—		50.3		—		—
Marketable securities	0.7		—		—		0.7		—		—
Total equity securities	48.0		—		—		51.0		—		—
Available-for-sale fixed income investments:
Corporate bonds	—		15.9		—		—		16.6		—
U.S. Treasuries	—		13.6		—		—		14.6		—
Agency mortgage-backed securities	—		2.5		—		—		2.0		—
Asset backed securities	—		4.1		—		—		4.6		—
Other	—		0.5		—		—		0.4		—
Total available-for-sale fixed income investments	—		36.6		—		—		38.2		—
Foreign exchange derivative assets	—		202.8		—		—		144.6		—

Total assets at recurring fair value measurement	$	48.4	$	239.4	$	—	$	101.9	$	182.8	$	—
Financial Liabilities

Foreign exchange derivative liabilities	—		98.9		—		—		61.0		—
Contingent consideration	—		—		198.4		—		—		199.7
Total liabilities at recurring fair value measurement	$	—	$	98.9	$	198.4	$	—	$	61.0	$	199.7

Designated as Hedging Instrument

Derivatives, Fair Value [Line Items]

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value

The following table summarizes the classification and fair values of derivative instruments in our condensed consolidated balance sheets:


	Asset Derivatives					Liability Derivatives
(In millions)	Balance Sheet Location	March 31, 2022 Fair Value		December 31, 2021 Fair Value		Balance Sheet Location	March 31, 2022 Fair Value		December 31, 2021 Fair Value

Derivatives designated as hedges:

Foreign currency forward contracts	Prepaid expenses & other current assets	$	63.9	$	62.0	Other current liabilities	$	7.6	$	4.3
Total derivatives designated as hedges		63.9		62.0			7.6		4.3
Derivatives not designated as hedges:
Foreign currency forward contracts	Prepaid expenses & other current assets	138.9		82.6		Other current liabilities	91.3		56.7
Total derivatives not designated as hedges		138.9		82.6			91.3		56.7
Total derivatives		$	202.8	$	144.6		$	98.9	$	61.0

Acquisitions and Other Transactions (Narrative) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Goodwill	$ 10,978.8	$ 12,113.7

Balance Sheet Components (Property, Plant and Equipment) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 5,092.5	$ 5,589.1
Accumulated depreciation	1,942.3	2,400.5
Property, plant and equipment, net	3,150.2	3,188.6
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,845.8	3,054.0
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,578.4	1,808.5
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	541.8	588.7
Land and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 126.5	$ 137.9

Goodwill and Intangible Assets (Changes in Carrying Amount of Goodwill) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($)
Goodwill [Roll Forward]
Goodwill, gross, beginning balance	$ 12,498.7
Accumulated impairment losses, beginning balance	(385.0)
Foreign currency translation	(181.9)
Goodwill, net, beginning balance	12,113.7
Accumulated impairment losses, ending balance	(385.0)
Goodwill, gross, ending balance	11,363.8
Goodwill, net, ending balance	10,978.8
Goodwill, Transfers	(953.0)
Developed Markets
Goodwill [Roll Forward]
Goodwill, gross, beginning balance	9,108.4
Accumulated impairment losses, beginning balance	(385.0)
Foreign currency translation	(172.2)
Goodwill, net, beginning balance	8,723.4
Accumulated impairment losses, ending balance	(385.0)
Goodwill, gross, ending balance	8,174.2
Goodwill, net, ending balance	7,789.2
Goodwill, Transfers	(762.0)
Greater China
Goodwill [Roll Forward]
Goodwill, gross, beginning balance	969.5
Accumulated impairment losses, beginning balance	0.0
Foreign currency translation	0.7
Goodwill, net, beginning balance	969.5
Accumulated impairment losses, ending balance	0.0
Goodwill, gross, ending balance	967.2
Goodwill, net, ending balance	967.2
Goodwill, Transfers	(3.0)
JANZ
Goodwill [Roll Forward]
Goodwill, gross, beginning balance	776.3
Accumulated impairment losses, beginning balance	0.0
Foreign currency translation	(0.4)
Goodwill, net, beginning balance	776.3
Accumulated impairment losses, ending balance	0.0
Goodwill, gross, ending balance	738.9
Goodwill, net, ending balance	738.9
Goodwill, Transfers	(37.0)
Emerging Markets
Goodwill [Roll Forward]
Goodwill, gross, beginning balance	1,644.5
Accumulated impairment losses, beginning balance	0.0
Foreign currency translation	(10.0)
Goodwill, net, beginning balance	1,644.5
Accumulated impairment losses, ending balance	0.0
Goodwill, gross, ending balance	1,483.5
Goodwill, net, ending balance	1,483.5
Goodwill, Transfers	$ (151.0)

Litigation (Product Liability) (Narrative) (Details) $ in Millions	Mar. 31, 2022 USD ($)
Product Liability
Loss Contingencies [Line Items]
Loss Contingency Accrual	$ 75.3

Debt (Fair Value) (Narrative) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Senior Notes
Debt Instrument [Line Items]
Fair value of long-term debt	$ 19,490	$ 22,010

Debt (Minimum Repayments on Outstanding Borrowings) (Details) $ in Millions	Dec. 31, 2021 USD ($)
Debt Disclosure [Abstract]
2022	$ 1,830
2023	1,250
2024	1,937
2025	1,303
2026	2,579
Thereafter	11,854
Total	$ 20,753

Litigation (MDRP Classification of EpiPen Auto-Injector and EpiPen Jr Auto-Injector) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Other Current Liabilities [Member]
Loss Contingencies [Line Items]
Estimated litigation liability	$ 269.0
EpiPen Auto-Injector Litigation
Loss Contingencies [Line Items]
Loss Contingency Accrual		$ 264.0

Balance Sheet Components (Other Long-term Obligations) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Schedule of Other Noncurrent Liabilities [Line Items]
Employee benefit liabilities	$ 861.3	$ 876.4
Contingent consideration	198.4	199.7
Tax related items, including contingencies	429.5	426.1
Operating Lease, Liability, Noncurrent	191.7	200.9
Restructuring Reserve, Noncurrent	51.4	64.3
Other	238.2	232.9
Other long-term obligations	1,884.3	1,933.6
Other long-term obligations
Schedule of Other Noncurrent Liabilities [Line Items]
Contingent consideration	$ 112.2	$ 133.0

General	3 Months Ended
General	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General	General The accompanying unaudited condensed consolidated financial statements (“interim financial statements”) of Viatris Inc. and subsidiaries were prepared in accordance with U.S. GAAP and the rules and regulations of the SEC for reporting on Form 10-Q; therefore, as permitted under these rules, certain footnotes and other financial information included in audited financial statements were condensed or omitted. The interim financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the interim results of operations, comprehensive earnings, financial position, equity and cash flows for the periods presented. These interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto in Viatris’ 2021 Form 10-K. The December 31, 2021 condensed consolidated balance sheet was derived from audited financial statements. Turkey Highly Inflationary - Under ASC 830, Foreign Currency Matters (“ASC 830”), a highly inflationary economy is one that has cumulative inflation of approximately 100% or more over a three-year period. Effective April 1, 2022, we classified Turkey as highly inflationary. In accordance with ASC 830, starting with the second quarter of 2022, we will begin to use the U.S. dollar as our functional currency in Turkey, which historically utilized the Turkish lira as the functional currency. The impacted net sales for the three months ended March 31, 2022 and total assets at March 31, 2022 represented less than 1% of our consolidated net sales and total assets, respectively. The interim results of operations, comprehensive earnings and cash flows for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the full fiscal year or any other future period.

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 752,400,000	$ 701,200,000
Accounts receivable, net	4,093,900,000	4,266,400,000
Inventories	3,797,300,000	3,977,700,000
Prepaid expenses and other current assets	1,763,600,000	1,957,600,000
Assets held for sale	1,337,100,000	0
Total current assets	11,744,300,000	10,902,900,000
Property, plant and equipment, net	3,150,200,000	3,188,600,000
Intangible assets, net	25,251,800,000	26,134,200,000
Goodwill	10,978,800,000	12,113,700,000
Deferred income tax benefit	1,285,800,000	1,332,700,000
Other assets	1,056,000,000	1,170,700,000
Total assets	53,466,900,000	54,842,800,000
Current liabilities:
Accounts payable	1,499,600,000	1,657,400,000
Short-term borrowings	655,400,000	1,493,000,000
Income taxes payable	177,800,000	236,900,000
Current portion of long-term debt and other long-term obligations	2,606,100,000	1,877,500,000
Liabilities held for sale	277,700,000	0
Other current liabilities	4,426,300,000	4,619,600,000
Total current liabilities	9,642,900,000	9,884,400,000
Long-term debt	18,762,500,000	19,717,100,000
Deferred income tax liability	2,729,500,000	2,815,000,000
Other long-term obligations	1,884,300,000	1,933,600,000
Total liabilities	33,019,200,000	34,350,100,000
Viatris Inc. shareholders’ equity
Common Stock, Value, Issued	12,100,000	12,100,000
Additional paid-in capital	18,555,100,000	18,536,100,000
Retained earnings	3,941,500,000	3,688,800,000
Accumulated other comprehensive loss	(2,061,000,000)	(1,744,300,000)
Total equity	20,447,700,000	20,492,700,000
Total liabilities and equity	$ 53,466,900,000	$ 54,842,800,000

General (Policies)	3 Months Ended
General (Policies)	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting Policy	The accompanying unaudited condensed consolidated financial statements (“interim financial statements”) of Viatris Inc. and subsidiaries were prepared in accordance with U.S. GAAP and the rules and regulations of the SEC for reporting on Form 10-Q; therefore, as permitted under these rules, certain footnotes and other financial information included in audited financial statements were condensed or omitted. The interim financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the interim results of operations, comprehensive earnings, financial position, equity and cash flows for the periods presented.
Earnings per Share Policy	Basic earnings (loss) per share is computed by dividing net earnings (loss) by the weighted average number of shares outstanding during the period. Diluted earnings (loss) per share is computed by dividing net earnings (loss) by the weighted average number of shares outstanding during the period increased by the number of additional shares that would have been outstanding related to potentially dilutive securities or instruments, if the impact is dilutive
Fair Value of Financial Instruments Policy	Fair value is based on the price that would be received from the sale of an identical asset or paid to transfer an identical liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: •Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. •Level 2: Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities. •Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value.

Segment Information (Tables)

3 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Reconciliation of Segment Information to Total Consolidated Information

Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information.


	Net Sales				Segment Profitability
	Three Months Ended March 31,				Three Months Ended March 31,

(In millions)	2022		2021		2022		2021
Reportable Segments:
Developed Markets	$	2,476.1	$	2,571.6	$	1,211.5	$	1,285.4
Greater China	573.1		591.9		417.7		404.9
JANZ	423.8		481.9		174.3		184.2
Emerging Markets	705.2		754.7		345.3		337.3
Total reportable segments	$	4,178.2	$	4,400.1	$	2,148.8	$	2,211.8

Reconciling items:
Intangible asset amortization expense					(648.1)		(684.4)
Intangible asset impairment charges					—		(83.4)
Globally managed research and development costs					(142.3)		(184.1)
Litigation settlements & other contingencies					(6.2)		(22.9)
Transaction related and other special items					(185.6)		(993.4)
Corporate and other unallocated					(459.2)		(509.8)
Earnings (loss) from operations					$	707.4	$	(266.2)

Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Net sales	$ 4,178.2	$ 4,400.1
Brands
Disaggregation of Revenue [Line Items]
Net sales	2,554.1	2,724.6
Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	390.8	328.9
Generics
Disaggregation of Revenue [Line Items]
Net sales	1,233.3	1,346.6
Lipitor
Disaggregation of Revenue [Line Items]
Net sales	440.1	464.6
Norvasc
Disaggregation of Revenue [Line Items]
Net sales	207.8	227.7
Lyrica ®
Disaggregation of Revenue [Line Items]
Net sales	171.7	187.8
Viagra ®
Disaggregation of Revenue [Line Items]
Net sales	129.8	139.6
EpiPen® Auto-Injectors
Disaggregation of Revenue [Line Items]
Net sales	88.8	103.7
Celebrex ®
Disaggregation of Revenue [Line Items]
Net sales	85.2	89.0
Effexor ®
Disaggregation of Revenue [Line Items]
Net sales	77.5	76.6
Zoloft ®
Disaggregation of Revenue [Line Items]
Net sales	73.1	76.6
Creon ®
Disaggregation of Revenue [Line Items]
Net sales	74.7	69.9
Xalabrands
Disaggregation of Revenue [Line Items]
Net sales	53.0	57.9
Amitiza ®
Disaggregation of Revenue [Line Items]
Net sales	41.8	45.9
Xanax ®
Disaggregation of Revenue [Line Items]
Net sales	40.0	45.1
Dymista ®
Disaggregation of Revenue [Line Items]
Net sales	44.0	40.3
Yupelri ®
Disaggregation of Revenue [Line Items]
Net sales	43.7	36.9
Developed Markets \| Brands
Disaggregation of Revenue [Line Items]
Net sales	1,298.7	1,403.7
Developed Markets \| Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	364.1	312.0
Developed Markets \| Generics
Disaggregation of Revenue [Line Items]
Net sales	813.3	855.9
Greater China \| Brands
Disaggregation of Revenue [Line Items]
Net sales	569.7	590.9
Greater China \| Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	0.0	0.0
Greater China \| Generics
Disaggregation of Revenue [Line Items]
Net sales	3.4	1.0
JANZ \| Brands
Disaggregation of Revenue [Line Items]
Net sales	249.0	284.0
JANZ \| Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	10.3	8.9
JANZ \| Generics
Disaggregation of Revenue [Line Items]
Net sales	164.5	189.0
Emerging Markets \| Brands
Disaggregation of Revenue [Line Items]
Net sales	436.7	446.0
Emerging Markets \| Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	16.4	8.0
Emerging Markets \| Generics
Disaggregation of Revenue [Line Items]
Net sales	252.1	300.7
Operating Segment \| Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	2,476.1	2,571.6
Operating Segment \| Greater China
Disaggregation of Revenue [Line Items]
Net sales	573.1	591.9
Operating Segment \| JANZ
Disaggregation of Revenue [Line Items]
Net sales	423.8	481.9
Operating Segment \| Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	$ 705.2	$ 754.7

Litigation (Intellectual Property) (Narrative) (Details) - Intellectual Property $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($) increase
Loss Contingencies [Line Items]
Number of times damages may be increased in cases of willful infringement \| increase	3
Damages to be paid \| $	$ 211.8

Comprehensive Earnings (Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax (benefit) provision	$ 128.3	$ 596.3
Net unrealized gain on marketable securities, net of tax	(1.3)		$ 0.0
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax	(29.4)		32.2
Foreign currency translation adjustment	(2,271.6)		(1,802.4)
Accumulated other comprehensive loss	(2,061.0)		(1,744.3)
Other comprehensive loss, before tax	(272.0)	(490.6)
Net unrealized loss on marketable securities	(1.7)	(0.9)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax	2.6	(0.8)
Sales Revenue, Goods, Net	4,178.2	4,400.1
Interest expense	146.2	169.0
Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gain (loss) on derivatives	0.2
Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulate Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Net Investment Hedges, Effect Net of Taxx	173.1		16.7
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax (benefit) provision		37.0
Accumulated other comprehensive loss		(1,385.6)		$ (858.0)
Other comprehensive earnings (loss) before reclassifications, before tax	(259.0)	(485.8)
Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax (benefit) provision		0.8
Net unrecognized loss on derivatives in cash flow hedging relationships, net of tax		(15.5)		(18.0)
Other comprehensive earnings (loss) before reclassifications, before tax		8.3
Gains and Losses on Derivatives \| Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax (benefit) provision	0.0
Net unrecognized loss on derivatives in cash flow hedging relationships, net of tax			$ 9.2
Other comprehensive earnings (loss) before reclassifications, before tax	13.3
Gains and Losses on Derivatives \| Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax (benefit) provision	44.9	35.1
Net unrecognized loss on derivatives in cash flow hedging relationships, net of tax		(161.3)		(353.6)
Other comprehensive earnings (loss) before reclassifications, before tax		227.4
Gains and Losses on Marketable Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax (benefit) provision		0.1
Net unrealized gain on marketable securities, net of tax		0.2		1.2
Other comprehensive earnings (loss) before reclassifications, before tax		(0.9)
Defined Benefit Plan Items
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax (benefit) provision		(1.0)
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax		(26.3)		(26.1)
Other comprehensive earnings (loss) before reclassifications, before tax	(2.7)	0.6
Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax (benefit) provision		0.0
Foreign currency translation adjustment		(1,182.7)		$ (461.5)
Other comprehensive earnings (loss) before reclassifications, before tax	(469.2)
Reclassification out of Accumulated Other Comprehensive Income [Member] \| AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax (benefit) provision	44.7
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax	(0.1)	0.1
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax		(0.3)
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gain (loss) on derivatives		3.3
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Gains and Losses on Marketable Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax (benefit) provision	(0.4)
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Defined Benefit Plan Items
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax (benefit) provision	0.2
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax		(0.8)
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax		(0.1)
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax (benefit) provision	0.0
Other comprehensive loss, before tax		(721.2)
Mylan N.V. \| Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gain (loss) on derivatives	201.3	227.4
Foreign currency forward contracts \| Gains and Losses on Derivatives \| Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sales Revenue, Goods, Net	(14.2)
Foreign currency forward contracts \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sales Revenue, Goods, Net	(14.2)	(6.1)
Foreign currency forward contracts \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sales Revenue, Goods, Net	(14.2)	(6.1)
Interest rate swaps \| Gains and Losses on Derivatives \| Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.1
Interest rate swaps \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.1	1.1
Interest rate swaps \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.1	1.1
Pension and other postretirement benefits
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax	(0.1)	0.1
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement	0.0	$ (0.3)
Pension and other postretirement benefits \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Defined Benefit Plan Items
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax	$ (0.1)

Acquisitions and Other Transactions (Purchase Price Allocations) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Goodwill	$ 10,978.8	$ 12,113.7

Financial Instruments and Risk Management (Effect Of Derivative Instruments on the Condensed Consolidated Statements of Operations, Derivatives Not Designated as Hedging Instruments) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Foreign currency forward contracts \| Other expense
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net	$ 21.7	$ 35.6

Balance Sheet Components (Other Assets) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Other Assets, Noncurrent [Abstract]
Operating lease right-of-use assets	$ 281.7	$ 290.8
Other long-term assets	774.3	879.9
Other assets	$ 1,056.0	$ 1,170.7

Goodwill and Intangibles Assets (Expected Amortization Expense) (Details) $ in Millions	Mar. 31, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 1,916
2023	2,392
2024	2,295
2025	2,198
2026	$ 2,141

Segment Information (Reconciliation Of Segment Information To Total Consolidated Information) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	$ 4,178.2	$ 4,400.1
Revenues	4,191.7	4,430.3
Amortization of Intangible Assets	(648.1)	(684.4)
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	0.0	(83.4)
Research and development	(142.3)	(184.1)
Litigation settlements and other contingencies, net	(6.2)	(22.9)
Earnings (loss) from operations	707.4	(266.2)
Operating Segment
Segment Reporting Information [Line Items]
Earnings (loss) from operations	2,148.8	2,211.8
Reconciling items:
Segment Reporting Information [Line Items]
Amortization of Intangible Assets	(648.1)	(684.4)
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	0.0	(83.4)
Research and development	(142.3)	(184.1)
Litigation settlements and other contingencies, net	(6.2)	(22.9)
Other One-Time Nonoperating Expense	(185.6)	(993.4)
Corporate / Other
Segment Reporting Information [Line Items]
Corporate costs	459.2	509.8
Developed Markets \| Operating Segment
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	2,476.1	2,571.6
Earnings (loss) from operations	1,211.5	1,285.4
Greater China \| Operating Segment
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	573.1	591.9
Earnings (loss) from operations	417.7	404.9
JANZ \| Operating Segment
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	423.8	481.9
Earnings (loss) from operations	174.3	184.2
Emerging Markets \| Operating Segment
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	705.2	754.7
Earnings (loss) from operations	$ 345.3	$ 337.3

Revenue Recognition and Accounts Receivable Variable Consideration (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
Gross sales	$ 7,198.3	$ 7,567.0
Chargebacks	(1,584.2)	(1,318.0)
Rebates, promotional programs and other sales allowances	(1,205.9)	(1,568.5)
Returns	(82.6)	(113.0)
Medicaid and other governmental rebates	(147.4)	(167.4)
Sales Revenue, Gross to net adjustments	(3,020.1)	(3,166.9)
Net sales	$ 4,178.2	$ 4,400.1

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Collaboration and Licensing Agreements	3 Months Ended
Collaboration and Licensing Agreements	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration and Licensing Agreements	Licensing and Other Partner AgreementsWe periodically enter into licensing and other partner agreements with other pharmaceutical companies for the development, manufacture, marketing and/or sale of pharmaceutical products. Our significant licensing and other partner agreements are primarily focused on the development, manufacturing, supply and commercialization of multiple, high-value generic biologic compounds, insulin analog products and respiratory products, among other complex products. Under these agreements, we have future potential milestone payments and co-development expenses payable to third parties as part of our licensing, development and co-development programs. Payments under these agreements generally become due and are payable upon the satisfaction or achievement of certain developmental, regulatory or commercial milestones or as development expenses are incurred on defined projects. Milestone payment obligations are uncertain, including the prediction of timing and the occurrence of events triggering a future obligation and are not reflected as liabilities in the condensed consolidated balance sheets, except for obligations reflected as acquisition related contingent consideration. Refer to Note 10 Financial Instruments and Risk Management for further discussion of contingent consideration. Our potential maximum development milestones not accrued for at March 31, 2022 totaled approximately $338 million. We estimate that the amounts that may be paid through the end of 2022 to be approximately $10 million. These agreements may also include potential sales-based milestones and call for us to pay a percentage of amounts earned from the sale of the product as a royalty or a profit share. The amounts disclosed do not include sales-based milestones or royalty or profit share obligations on future sales of product as the timing and amount of future sales levels and costs to produce products subject to these obligations is not reasonably estimable. These sales-based milestones or royalty or profit share obligations may be significant depending upon the level of commercial sales for each product. There have been no significant changes to our licensing and other partner agreements as disclosed in our 2021 Form 10-K.

Earnings (Loss) per Ordinary Share (Narrative) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions			3 Months Ended
	May 05, 2022	Mar. 16, 2022	Mar. 31, 2022	Mar. 31, 2021	Feb. 28, 2022
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Diluted (in USD per share)			$ 0.33	$ (0.86)
Anti-dilutive stock options or restricted stock awards excluded from computation of earnings per share			15.5	10.9
Dividends paid (in dollars per share)		$ 0.12
Share repurchase program, authorized amount					$ 1,000
Subsequent Event
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Dividends declared (in dollars per share)	$ 0.12
Dividends payable (in dollars per share)	$ 0.12

- Definition

+ References

+ Details

Condensed Consolidated Balance Sheets (Parenthetical) - € / shares	Mar. 31, 2022	Dec. 31, 2021
Ordinary shares, nominal value	€ 0.01
Ordinary shares, shares authorized		3,000,000,000

Revenue Recognition and Accounts Receivable (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Proceeds from sale and collection of receivables	$ 55.1	$ 29.6

Goodwill and Intangible Assets (Narrative) (Details) - USD ($) $ in Millions		3 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
In-process research and development	$ 45.7	$ 45.7		$ 46.5
Contingent consideration	198.4	198.4		199.7
Business Combination Contingent Consideration Liability Payments		(15.5)
Intangible asset impairment charges		0.0	$ 83.4
Goodwill	10,978.8	10,978.8		12,113.7
Greater China
Finite-Lived Intangible Assets [Line Items]
Reporting Unit, Amount of Fair Value in Excess of Carrying Amount	$ 797.0	$ 797.0
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount	5.30%	5.30%
Good will, After Amortization Expense, Before Reclassification	$ 4,950.0	$ 4,950.0
Greater China \| Measurement Input, Long-term Revenue Growth Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(0.005)	(0.005)
Greater China \| Valuation Technique, Discounted Cash Flow
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input, Term	10 years
Greater China \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Long-term Revenue Growth Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(0.095)	(0.095)
Greater China \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Terminal Year Revenue Growth Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(0.010)	(0.010)
Greater China \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Estimated Tax Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(0.153)	(0.153)
Greater China \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Control Premium
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(0.150)	(0.150)
Greater China \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Reduction in Terminal Year Revenue Growth Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	0.030	0.030
Greater China \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Increase in Discount Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(0.015)	(0.015)
North America Segment
Finite-Lived Intangible Assets [Line Items]
Good will, After Amortization Expense, Before Reclassification	$ 3,610.0	$ 3,610.0
Emerging Markets
Finite-Lived Intangible Assets [Line Items]
Goodwill	1,483.5	1,483.5		1,644.5
Reporting Unit, Amount of Fair Value in Excess of Carrying Amount	$ 816.0	$ 816.0
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount	10.30%	10.30%
Good will, After Amortization Expense, Before Reclassification	$ 1,640.0	$ 1,640.0
Emerging Markets \| Valuation Technique, Discounted Cash Flow
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input, Term	10 years
Emerging Markets \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Long-term Revenue Growth Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(0.016)	(0.016)
Emerging Markets \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Terminal Year Revenue Growth Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(0.008)	(0.008)
Emerging Markets \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Estimated Tax Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(0.184)	(0.184)
Emerging Markets \| Valuation Technique, Discounted Cash Flow \| Measurement Input, EBITDA Multiple
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(7.5)	(7.5)
Emerging Markets \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Reduction in Terminal Year Revenue Growth Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	0.085	0.085
Emerging Markets \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Increase in Discount Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(0.030)	(0.030)
Emerging Markets \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Discount Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(0.105)	(0.105)
JANZ
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 738.9	$ 738.9		776.3
Reporting Unit, Amount of Fair Value in Excess of Carrying Amount	$ 231.0	$ 231.0
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount	7.40%	7.40%
Good will, After Amortization Expense, Before Reclassification	$ 780.0	$ 780.0
JANZ \| Valuation Technique, Discounted Cash Flow
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input, Term	10 years
JANZ \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Long-term Revenue Growth Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(0.048)	(0.048)
JANZ \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Terminal Year Revenue Growth Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	0	0
JANZ \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Estimated Tax Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(0.304)	(0.304)
JANZ \| Valuation Technique, Discounted Cash Flow \| Measurement Input, EBITDA Multiple
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(6.0)	(6.0)
JANZ \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Control Premium
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(0.150)	(0.150)
JANZ \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Reduction in Terminal Year Revenue Growth Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	0.035	0.035
JANZ \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Increase in Discount Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(0.020)	(0.020)
JANZ \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Discount Rate
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(0.060)	(0.060)
Greater China
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 967.2	$ 967.2		969.5
Good will, After Amortization Expense, Before Reclassification	$ 970.0	$ 970.0
Minimum \| Greater China \| Valuation Technique, Discounted Cash Flow \| Measurement Input, EBITDA Multiple
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(7.5)	(7.5)
Maximum \| Greater China \| Valuation Technique, Discounted Cash Flow \| Measurement Input, EBITDA Multiple
Finite-Lived Intangible Assets [Line Items]
Goodwill Impairment, Measurement Input	(8.0)	(8.0)
Other Current Liabilities [Member]
Finite-Lived Intangible Assets [Line Items]
Contingent consideration	$ 86.2	$ 86.2		$ 66.7
Business Combination Contingent Consideration Liability Payments		(15.5)
Reconciling items:
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment charges		$ 0.0	$ 83.4

Goodwill and Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Changes in Carrying Amount of Goodwill

The changes in the carrying amount of goodwill for the three months ended March 31, 2022 are as follows:


(In millions)	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Balance at December 31, 2021:
Goodwill	$	9,108.4	$	969.5	$	776.3	$	1,644.5	$	12,498.7
Accumulated impairment losses	(385.0)		—		—		—		(385.0)
	8,723.4		969.5		776.3		1,644.5		12,113.7
Reclassification to assets held for sale	(762.0)		(3.0)		(37.0)		(151.0)		(953.0)
Foreign currency translation	(172.2)		0.7		(0.4)		(10.0)		(181.9)
	$	7,789.2	$	967.2	$	738.9	$	1,483.5	$	10,978.8
Balance at March 31, 2022:
Goodwill	$	8,174.2	$	967.2	$	738.9	$	1,483.5	$	11,363.8
Accumulated impairment losses	(385.0)		—		—		—		(385.0)
	$	7,789.2	$	967.2	$	738.9	$	1,483.5	$	10,978.8

Components of Intangible Assets

Intangible assets consist of the following components at March 31, 2022 and December 31, 2021:


(In millions)	Weighted Average Life (Years)	Original Cost		Accumulated Amortization		Net Book Value
March 31, 2022
Product rights, licenses and other (1)	15	$	38,550.7	$	13,344.6	$	25,206.1
In-process research and development		45.7		—		45.7
		$	38,596.4	$	13,344.6	$	25,251.8
December 31, 2021
Product rights, licenses and other (1)	15	$	39,006.2	$	12,918.5	$	26,087.7
In-process research and development		46.5		—		46.5
		$	39,052.7	$	12,918.5	$	26,134.2

____________

(1)Represents amortizable intangible assets. Other intangible assets consists principally of customer lists and contractual rights.

Finite-lived Intangible Assets Amortization Expense


	Three Months Ended
	March 31,
(In millions)		2022		2021
Intangible asset amortization expense		$	648.1	$	684.4
Intangible asset impairment charges		—		83.4

Total intangible asset amortization expense (including impairment charges)		$	648.1	$	767.8

Expected Amortization Expense

Intangible asset amortization expense over the remainder of 2022 and for the years ending December 31, 2023 through 2026 is estimated to be as follows:


(In millions)
2022	$	1,916
2023	2,392
2024	2,295
2025	2,198
2026	2,141

Earnings (Loss) per Ordinary Share (Tables)

3 Months Ended

Mar. 31, 2022

Earnings Per Share [Abstract]

Basic and Diluted Earnings per Ordinary Share Attributable to Mylan N.V.

Basic and diluted earnings (loss) per share attributable to Viatris Inc. are calculated as follows:


	Three Months Ended
	March 31,
(In millions, except per share amounts)		2022		2021
Basic earnings (loss) attributable to Viatris Inc. common shareholders
Net earnings (loss) attributable to Viatris Inc. common shareholders		$	399.2	$	(1,037.6)
Shares (denominator):
Weighted average shares outstanding		1,210.5		1,207.5
Basic earnings (loss) per share attributable to Viatris Inc. shareholders		$	0.33	$	(0.86)

Diluted earnings (loss) attributable to Viatris Inc. common shareholders
Net earnings (loss) attributable to Viatris Inc. common shareholders		$	399.2	$	(1,037.6)
Shares (denominator):
Weighted average shares outstanding		1,210.5		1,207.5
Share-based awards		2.6		—
Total dilutive shares outstanding		1,213.1		1,207.5
Diluted earnings (loss) per share attributable to Viatris Inc. shareholders		$	0.33	$	(0.86)